ЛИГАНД КОМПЛЕКСА РУТЕНИЯ, КОМПЛЕКС РУТЕНИЯ, КАТАЛИЗАТОР КОМПЛЕКСА РУТЕНИЯ И СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Изобретение относится к разновидности лигандов комплексов рутения и иммобилизированных катализаторов комплекса рутения. Изобретение также относится к получению и применению комплексов рутения и иммобилизированных катализаторов комплекса рутения. Лиганд комплекса рутения I и комплекс рутения II по настоящему изобретению имеют следующие структурные формулы: ! ! Катализаторы комплекса рутения по настоящему изобретению имеют следующие структурные формулы IV: ! ! ! В настоящем изобретении комплексы рутения и иммобилизированные катализаторы комплекса рутения имеют значительные преимущества, например, высокую каталитическую активность, высокую стабильность, простоту регенерации и повторного использования. 7 н. и 15 з.п. ф-лы, 6 табл., 4 ил.

ПОЛИМЕРНЫЙ КОНЪЮГАТ ГЕКСАКООРДИНИРОВАННОГО КОМПЛЕКСА ПЛАТИНЫ

Изобретение относится к полимерным конъюгатам гексакоординированного комплекса платины. Предложен полимерный конъюгат гексакоординированного комплекса платины, в котором гексакоординированный комплекс платины, содержащий галогены и гидроксильные группы в аксиальных положениях, напрямую или через спейсеры связаны с карбоксильными группами боковой цепи блок-сополимера, содержащего полиэтиленгликолевый структурный фрагмент и фрагмент полиаспарагиновой кислоты или фрагмент полиглутаминовой кислоты. Технический результат – предложенный конъюгат эффективно высвобождает высокоактивный комплекс платины в восстановительных условиях, в том числе в клетках. 6 н. и 10 з.п. ф-лы, 2 ил., 7 табл., 21 пр.

ВЫСОКОЭФФЕКТИВНЫЕ МЕТАТЕЗИСТИЧЕСКИЕ КАТАЛИЗАТОРЫ, ВЫБИРАЕМЫЕ В РЕАКЦИЯХ ROMP И RCM

Изобретение относится к лиганду координационного соединения металла. Лиганд имеет следующую структуру формулы Ia или Ibгде Ζ представляет собой СН=; m=0 или 1, n=0 или 1; при m=0, Υ представляет собой ΝΗ, С-С-алкилимино или С-С-арилимино; при m=1, X представляет собой СН; Υ представляет собой ΝΗ или С-С-алкилимино;представляет собой одинарную связь; при n=1, Xпредставляет собой СНили карбонил; Υпредставляет собой кислород или карбонил; Rпредставляет собой водород; Rпредставляет собой С-С-алкил или С-С-арил; Ε представляет собой водород, галоген, нитро, С-С-алкокси, С-С-алкоксикарбонил или С-С-алкиламиносульфонил; Еи Енезависимо представляют собой водород или галоген; Εпредставляет собой водород; Епредставляет собой водород или С-С-алкил; Еи Епредставляют собой водород, галоген, С-С-алкил или C-С-алкокси; Епредставляет собой водород или С-С-алкил. Также предложены координационное соединение переходного металла, способ проведения реакции метатезиса с олефиновым субстратом, применение координационного ...

УСИЛИТЕЛИ АДГЕЗИИ РЕЗИНЫ

Изобретение относится к металлоорганическим соединениям, к содержащим их составам и их использованию. Вулканизуемая резиновая смесь содержит натуральный каучук, один или несколько традиционных компонентов резиновой смеси и, по меньшей мере, одно металлоорганическое соединение в качестве усилителя адгезии общей формулы X(OMA'p )m(OMB'q)n, где Х представляет собой алюминий, титан, цирконий или кремний, алкил- или арилкремний или диалкил-, диарил- или алкиларилкремний; М - кобальт или никель; А' - радикал алифатической карбоновой кислоты с 7-15 атомами углерода; В' - радикал ароматической карбоновой кислоты с 7-15 атомами углерода или алифатической или ароматической арилоксикарбоновой кислоты с 8-15 атомами углерода; р и q - независимо от 0,5 до 1,5; m+n=x, где х представляет собой валентность X, m/n равно 0,67-9,0 и n равно 0, 2-(х-1). Резина состоит из резиновой смеси, включающей, по крайней мере, один усилитель адгезии и одну или несколько добавок. Технический результат состоит в усилении ...

КАРБОКСИЛАТНЫЕ СОЕДИНЕНИЯ БЛАГОРОДНЫХ МЕТАЛЛОВ Ir, Ru, Rh, Pd, Pt И Au, ОБЛАДАЮЩИЕ ВЫСОКОЙ КАТАЛИТИЧЕСКОЙ ЭФФЕКТИВНОСТЬЮ

Изобретение относится к способу получения карбоксилатных соединений благородного металла или их растворов. Благородный металл выбран из группы, состоящей из рутения, иридия, платины, палладия, родия и золота. Металл плавят с пероксидом щелочноземельного металла, после чего плавленую массу растворяют в карбоновой кислоте или карбоновой кислоте, разбавленной протонным растворителем. Из получаемого в результате раствора ионы щелочноземельного металла удаляют в виде соли щавелевой кислоты или соли производного щавелевой кислоты. Карбоксилатные соединения благородного металла обладают высокой каталитической активностью, а способ их получения является простым. 6 н.п. ф-лы, 4 пр.

СПОСОБ ПОЛУЧЕНИЯ ПОЛИМЕРИЗОВАННЫХ КООРДИНАЦИОННЫХ СОЕДИНЕНИЙ КОМПЛЕКСА ПЛАТИНЫ

Изобретение относится к способу получения конъюгата блок-сополимера и комплекса платины, который может быть использован в качестве противоопухолевого средства. Способ включает взаимодействие в водной среде комплекса диаквоплатины или бис(нитрато)платины в смеси с дигалогеноплатиной с блок-сополимером, формулы (1) или (2): ! ! ! где R1- водород или C1-C12-алкил, L1 и L2 - соединительные группы, R3 - водород, защитная группа для аминогруппы, гидрофобная или полимеризуемая группа, R4 - гидрокси-, карбокси- или гидрофобная группа, R5 - водород, ион щелочного металла или защитная группа для карбоксильной группы, m=5-20000, n=10-60, при условии, что R5 - водород или ион щелочного металла составляет 50% и более в n звеньях. Предложенный способ обеспечивает получение не содержащего иона серебра конъюгата, раствор которого обладает более узким распределением частиц по размеру. 2 н. и 15 з.п. ф-лы, 11 ил.

ДИБЕНЗИЛИДЕНАЦЕТОНОВЫЕ КОМПЛЕКСЫ ПАЛЛАДИЯ (0)

Изобретение относится к композиции, используемой для реакции С-С присоединения. Композиция содержит дибензилиденацетоновые комплексы палладия (0) формулы Pd(dba)с соотношением у/х в интервале от 1,5 до 3 и нерастворимые в хлорсодержащих углеводородах компоненты в количестве до 0,5% масс. Также предложены применение композиции и способ ее получения. Изобретение позволяет получить дибензилиденацетоновые комплексы палладия с высокой степенью чистоты. 3 н. и 5 з.п. ф-лы, 7 пр.

ПРОИЗВОДНЫЕ ПОРФИРИНПЛАТИНЫ, ТЕРАПЕВТИЧЕСКИЕ АКТИВНОЕ СОЕДИНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ОПУХОЛЕЙ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО СРЕДСТВА

... 1. Производные порфиринплатины, представляющие собой производные тетраарилпорфиринплатины общей формулы I где Х выбран из группы, содержащей О, S, NH, N-алкил; R2 и R3 выбраны из группы, содержащей Н, алкил, арил, аралкил, гетарил, гетарилалкил, циклоалкил; R4 выбран из группы, содержащей Н, алкил, арил, аралкил, гетарил, гетарилалкил, циклоалкил; R5 выбран из группы, содержащей Н, алкил, О-алкил, S-алкил, галоген, нитро, циано, амино, замещенную аминогруппу; R6 выбран из группы, содержащей Н, алкил, О-алкил, S-алкил, галоген, нитро, циано, амино, замещенную аминогруппу; или общей формулы II где X выбран из группы, = содержащей О, S, NH, N-алкил; R1, R2, R3 и R4 выбраны из группы, содержащей Н, алкил, арил, аралкил, гетарил, гетарилалкил, циклоалкил и R2-Z-R3, где Z означает (СН2)n, n равно 0-6; R1 и R4 могут означать -(CH2)n-COOR8, где n равно 0-6; R5 выбран из группы, содержащей Н, алкил, арил, аралкил, гетарил, гетарилалкил, циклоалкил; R6 выбран из группы, содержащей Н, алкил, O-алкил ...

СПОСОБ ПОЛУЧЕНИЯ ПОЛИМЕРИЗОВАННЫХ КООРДИНАЦИОННЫХ СОЕДИНЕНИЙ КОМПЛЕКСА ПЛАТИНЫ

... 1. Способ получения координационного соединения в результате проведения реакции между комплексом платины и полимером, имеющим карбоксильные группы в своих боковых цепях, ! где в качестве комплекса платины используют комплекс диаквоплатина или комплекс бис(нитрато)платина в виде смеси с комплексом дигалогеноплатина, который выбирают из комплексов дихлоро-, дииодо- или дибромоплатина, а в качестве полимера используют блок-сополимер, описывающийся следующими общими формулами (1) или (2) ! ! где R1 представляет собой атом водорода или незамещенную или замещенную линейную или разветвленную С1-С12 алкильную группу, L1 и L2 независимо друг от друга представляют собой соединительные группы, R2 представляет собой метиленовую группу или этиленовую группу, R3 представляет собой атом водорода, защитную группу для аминогруппы, гидрофобную группу или полимеризуемую группу, R4 представляет собой гидроксильную группу, защищенную карбоксильную группу, образованную совместно с концевым -СО, или гидрофобную ...

СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ, СОЕДИНЕНИЯ, КОМПЛЕКСНЫЙ МЕТАЛЛООРГАНИЧЕСКИЙ КАТАЛИЗАТОР

... 1. Способ получения соединения формулы (I)в которой R1 и R2 могут быть одинаковыми или различными и по отдельности представляют собой замещенную или незамещенную группу, выбранную из алкильной, циклоалкильной, арильной, алкилокси-, циклоалкилокси-, арилокси, алкиламино-, циклоалкиламино, ариламино, металлоценильной группы;R3, R4, R5, R6 могут быть одинаковыми или различными и по отдельности представляют собой атом водорода либо замещенную или незамещенную группу, выбранную из алкильной, циклоалкильной, арильной, алкилокси-, циклоалкилокси-, арилокси-, алкиламино-, циклоалкиламино-, ариламиногруппы;Е представляет собой замещенную или незамещенную группу, выбранную из PR7R8, P(BH)R7R8, -CH-PR7R8, -CH-P(BH)R7R8, -BR9R10, -CR11R12OH, -COR11, -SiR11R12R13; -SiR11R12-CH-PR7R8;где R7 и R8 могут быть одинаковыми или различными и по отдельности представляют собой водород, замещенную или незамещенную группу, выбранную из алкильной, циклоалкильной, арильной, алкилокси-, циклоалкилокси-, арилокси, ...

ОДНОСТАДИЙНЫЙ СПОСОБ ПОЛУЧЕНИЯ 1,3-ПРОПАНДИОЛА ИЗ ЭТИЛЕНОКСИДА И СИНТЕЗ-ГАЗА С КАТАЛИЗАТОРОМ С ФОСФОЛАНОАЛКАНОВЫМ ЛИГАНДОМ

... 1. Каталитическая композиция, включающая а) кобальтовый компонент, включающий одно или более не лигированных соединений кобальта; и b) рутениевый компонент, включающий в основном соединение карбонила рутения лигированное с фосфоланоалкановым лигандом. 2. Каталитическая композиция по п.1, растворенная в эфирном растворителе. 3. Композиция по п.1 или 2, где фосфоланоалкан представляет собой где, в обеих формулах I и II, R является низшим алкилом, трифторметилом, фенилом, замещенным фенилом, аралкилом или замещенным в кольце аралкилом; и n равно целому числу от 1 до 12; и А в формуле II является ССН3, СН, N или Р. 4. Композиция по п.3, в которой в обеих формулах I и II R является низшим алкилом С1-С6 алкилом, и n равно от 1 до 3. 5. Композиция по п.4, в которой в формулах I и II R является метилом. 6. Композиция по п.1, в которой фосфоланоалкан выбирают из группы, включающей 1,2-бис(фосфолано)этан; 1,2-бис(2,5-диметилфосфолано)этан; 1, 2-бис[(2R,5R)-2,5-диметилфосфолано]этан; 1,2-бис[(2S,5S ...

Aromatische Monomer- und konjugierte Polymer-Metallkomplexe

Halogenierte aromatische Monomer-Metallkomplexverbindung, welche ein halogeniertes aromatisches Monomerfragment und ein Metallkomplexfragment umfasst und durch die folgende Struktur dargestellt ist: wobei L ein zweizähniger Ligand ist; M Ir, Rh oder Os ist; Ar' oder Ar'' aromatische Einheiten sind, welche gleich oder voneinander verschieden sein können, mit der Maßgabe, dass mindestens eines von Ar' und Ar'' heteroaromatisch ist; und wobei Ra und Rb jeweils unabhängig voneinander ein einwertiger Substituent oder H sind, mit der Maßgabe, dass mindestens eines von Ra und Rb ein halogeniertes aromatisches Monomerfragment und einen Verbindungsrest enthält, welcher die Konjugation zwischen dem halogenierten aromatischen Monomerfragment und dem Metallkomplexfragment unterbricht.

PROCESS FOR PREPARING RHODIUM (I) CARBONYL COMPLEXES

VERFAHREN ZUR HERSTELLUNG VON AMIN-PLATIN-KOMPLEXEN

HERSTELLUNG VON POLYMERISATIONSKATALYSATOREN

Light-emitting compound

Metal complex, polymer compound and device containing it

Ruthenium complex and its use in a dye-sensitized solar cell

... 1. A ruthenium complex, which is represented by the following formula (I):RuL2(NCS)2Am(I)whereinL is 2,2'-bipyridyl-4,4'-dicarboxylic acid, 2,2'-bipyridyl-4,4'-disulfonic acid, or 2,2'-bipyridyl-4,4'-diphosphonic acid;A is a quaternary phosphonium cation; andm is 1, 2, 3, or 4. The ruthenium complex can be used in a Dye-Sensitized Solar Cell (DSSC). Hence, the photoelectric characteristics of the DSSC manufactured witn the ruthenium complex of the present invention can be improved.

Fused ring metal complex, polymer compound and device containing it

Dendrimer compound and organic luminescent element employing the same

Metal complex,polymeric compound,and element comprising these

ALCOHOLATES OF THE RARE-EARTH METALS AS PRELIMINARY STAGES FOR METALLOXIDSCHICHTEN AND - FILMS

PROCEDURE FOR THE PRODUCTION OF PALLADIUM (0) - HALTIGEN CONNECTIONS

METALLKOMPLEXE ENTHALTEND EINEN 2,6-DIACYLPYRIDIN-LIGANDEN UND DEREN VERWENDUNG BEI DER POLYMERISATION VON ETHYLEN

METAL COMPLEXES CONTAINING a 2,6-DIACYLPYRIDIN-LIGANDEN AND THEIR USE WITH the POLYMERIZATION OF ETHYLS

VERFAHREN ZUR HERSTELLUNG EINES NEUEN STABILEN HOMOGENEN RHODIUM-HYDRIERUNGS-KATALYSATORS UND DESSEN ANWENDUNG

METAL COMPLEXES

IRIDIUM-ORGANIC COMPLEX AND ELECTRICAL LUMINESCENCE EQUIPMENT, IN WHICH THIS IS USED

RUTHENIUM COMPLEXES WITH ANTI-CANCER EFFECT

METAL COMPLEX CONNECTION AND ORGANIC ELEKTROLUMINESZENTES ELEMENT, WITH WHICH THIS IS USED

3,4-DIMETHYL-2,5-6-TRIS (P-SULFONATOPHENYL) - 1PHOSPHANORBORNADIEN, PROCEDURE FOR ITS PRODUCTION AND PROCEDURE FOR HYDROFORMYLIERUNG OF OLEFINISCH INSATIATED CONNECTIONS

PROCEDURE FOR THE RECUPERATION OF RHODIUM FROM RHODIUM COMPLEX CONNECTIONS ABSTENTION WAESSRIGEN LOESUNGEN.

AMMINE N HETERO-CYCLIC PLATINUM COMPLEXES AND ANTI-TUMOR MEANS.

Procedure for the electro-chemical production of CO-free metal-organic complexes of transition metals

PROCEDURE FOR THE PRODUCTION OF METAL COMPLEXES

ASYMMETRICAL HYDROGENATION OF BETA OR GAMMA KETOESTERN AND OF BETA OR GAMMA KETOAMIDEN

SULFONIERTE PHENYLPHOSPHANE ABSTENTION COMPLEX CONNECTIONS

SULFONIERTE PHENYLPHOSPHANE ABSTENTION COMPLEX CONNECTIONS

ADHESION MEDIATOR FOR INDIA RUBBER

METHOD FOR THE REDUCTION OF THE POLLUTANT OUTPUT FROM A WITH A CASE OF PARTICLE PROVIDED DIESEL ENGINE

Metal complexes comprising a 2,6-diacylpyridine-ligand and their use in the polymerization of ethylene

BIMETALLIC CLUSTERS OF RUTHENIUM WITH COPPER, SILVER AND GOLD

ANTI-TUMOR PLATINUM COMPLEXES, THEIR PREPARATION AND THEIR THERAPEUTIC USE

Metallocenyl-phthalocyanines

New catalyst structure for olefin polymerization

NEW CATALYST STRUCTURE FOR OLEFIN POLYMERIZATION

Highly active metathesis catalysis selective for ROMP and RCM

A kind of novel carbene ligand and corresponding novel ruthenium catalyst are provided. The ruthenium catalysts are highly active and selective for ROMP and RCM reactions. The significant electronic effects of different substituted carbene ligands on the catalytic activity and stability of corresponding carbene ruthenium complexes are disclosed. The methods for preparing new ruthenium complexes are disclosed. Moreover, efficient methods for making various functional polymers and quality modified nitrile butadiene rubbers via different metathesis and hydrogenation reactions in the presence of the new ruthenium catalysts are provided.

WATER AND SOLVENT SOLUBLE AXIAL HYDROXY AND MONO- AND DI- CARBOXYLIC ACID DERIVATIVES HAVING HIGH TUMOR ACTIVITY

RUTHENIUM ANTICANCER COMPLEXES

Ruthenium complex and photoelectric component using the same

RUTHENIUM COMPLEX AND PHOTOELECTRIC COMPONENT USING THE The present invention relates to a ruthenium complex and a photoelectric component 5 using the same, and the ruthenium complex is represented by the following formula (I): RuL 2(NCS)2Am (I) wherein L, A and m are defined the same as the specification. The ruthenium complex of the present invention is suitable for Dye-Sensitized Solar Cell (DSSC). io Hence, the photoelectric characteristics of the DSSC manufactured with the ruthenium complex of the present invention can be improved.

TITANOCENE PHOTOINITIATOR

ORGANO-METAL COMPOSITIONS, PREPARATION AND USE

Imidazolidine-based metal carbene metathesis catalysts

3,4-dimethyl-2,5,6-tris(p-sulfonatophenyl)- 1-phosphanorbornadiene, process for the preparation thereof and process for the hydroformylation of olefinically unsaturated compounds

Imidazolidine-based metal carbene metathesis catalysts

COMPLEX COMPOUNDS CONTAINING SULFONATED PHENYL PHOSPHANES

HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS

A kind of novel carbene ligand and corresponding novel ruthenium catalyst are provided. The ruthenium catalysts are highly active and selective for ROMP and RCM reactions. The significant electronic effects of different substituted carbene ligands on the catalytic activity and stability of corresponding carbene ruthenium complexes are disclosed. The methods for preparing new ruthenium complexes are disclosed. Moreover, efficient methods for making various functional polymers and quality modified nitrile butadiene rubbers via different metathesis and hydrogenation reactions in the presence of the new ruthenium catalysts are provided.

PALLADIUM PRECURSOR COMPOSITION

A non-catalytic palladium precursor composition is disclosed, including a palladium salt and an organoamine, wherein the composition is substantially free of water. The composition permits the use of solution processing methods to form a palladium layer on a wide variety of substrates, including in a pattern to form circuitry or pathways for electronic devices.

(GEM-HETEROCYCLODIMETHANAMINE-N,N')PLATINUM COMPLEXES

... (Gem-HETEROCYCLODIMETHANAMINE-N,N')PLATINUM COMPLEXES Organic platinum complexes active as anti-tumor agents in warm-blooded animals, and methods for synthesis of same, are described.

ANTI-TUMOR PLATINUM COMPLEXES, THEIR PREPARATION AND THEIR THERAPEUTIC USE

Compounds of formula (I): (I) in which: A and B are separately monoamines or together diamines; and Z is a group of formula (II) or (III): (II) (III) (in which R1, R2 and R7 are various organic groups, n is 0, 1 or 2 and X is a direct carbon-carbon bond or lower alkylene) show valuable anti-tumor activity and may be prepared by reacting an amine-platinum complex with a compound providing the group represented by Z.

CATALYST COMPLEX WITH CARBENE LIGAND

Catalytic complexes including a metal atom having anionic ligands, at least one nucleophilic carbene ligand, and an alkylidene, vinylidene, or allenylidene ligand. The complexes are highly stable to air, moisture and thermal degradation. The complexes are designed to efficiently carry out a variety of olefin metathesis reactions.

CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION

A process for preparing the S or R enantiomer of a compound of formula A, the process comprising subjecting a compound of formula B to asymmetric hydrogenation in the presence of a chiral catalyst and a source of hydrogen, wherein: X is CH2, oxygen or sulphur; R-1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group; and R4 is alkyl or aryl, wherein: the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means a phenyl or naphthyl group, optionally substituted by alkyloxy, halogen or nitro group; and the term halogen means fluorine, chlorine, bromine or iodine.

3,4-Dimethyl-2,5,6-Tris(P-Sulfonatophenyl) -1-Phosphanorbornadiene, Process for the Preparation Thereof and Process for the Hydroformylation of Olefinically Unsaturated Compounds

COMPLEX COMPOUNDS CONTAINING SULFONATED PHENYL PHOSPHANES

METAL COMPLEXES WITH HETEROCYCLIC CARBENES

The invention relates to novel complexes of elements of groups 8, 9 ana lo of the periodic table with heterocyclic carbenes as ligands.

RUTHENIUM AND OSMIUM CARBENE CATALYSTS

The invention relates to penta- and hexacoordinated ruthenium and osmium carbene catalysts, in which a sulfur, oxygen or nitrogen atom is attached to the carbene group which is coordinated with the central ruthenium or osmium atom, to their preparation and to their use for synthesizing polymers, for ring-closing metathesis of olefins and for isomerizing olefins.

METHOD FOR PRODUCING RUTHENIUM COMPLEXES

The invention relates to ruthenium complexes of the general formulas (I) RuX2(=CH-CH2R)L1L2 or (IV) RuXY(=CH-CH2R)L1L2, where X, Y are anionic ligands, R is hydrogen or a possibly substituted C1-C20 alkyl rest or C6-C20 aryl rest, and L1 and L2 independently of each other are neutral electron donor ligands. Said ruthenium complexes are produced by (a) reacting RuX3 with L1 and L2 in an inert solvent in the presence of a reducing agent and hydrogen, and (b) by reacting the resulting product with compounds of the general formula (II) RCCH, where R has the meaning given above, possibly in the presence of water and possibly after isolation of the intermediate stage with HY, (HL1)Y or (HL2)Y.

Verfahren zur Herstellung von Komplexverbindungen

Verfahren zur Herstellung von Komplexverbindungen von Dithiocarbamaten

NEW PLATINUM CONNECTIONS AND PROCEDURES FOR YOUR PRODUCTION AS WELL AS PROCEDURES FOR THE PRODUCTION FROM IT ABSTENTIONS MEDICAL PREPARATIONS TO THE TREATMENT OF CANCER.

RUTHENIUM COMPLEX.

La presente invenzione si riferisce ad un complesso di rutenio rappresentato dalla formula (I) seguente:
RuLL´X2
(I)
in cui L, L´ e X hanno lo stesso significato definito nella descrizione. Il complesso di rutenio della presente invenzione è adatto per una cella solare sensibilizzata con colorante (DSSC) e presenta buone caratteristiche fotoelettriche.

Complex of ruthenium and photoelectric member whom the same one uses.

La presente invenzione si riferisce a un complesso di rutenio e a un componente fotoelettrico che usa lo stesso, e il complesso di rutenio è rappresentato mediante la seguente formula (I): RuL 2 (NCS) 2 A m (I) in cui L, A ed m sono definiti come per la specifica. Il complesso di rutenio della presente invenzione è idoneo per una cella solare sensibilizzata con coloranti (DSSC). Pertanto, le caratteristiche fotoelettriche della DSSC prodotta con il complesso di rutenio della presente invenzione possono essere migliorate.

Solar cell with ruthenium complex.

La presente invenzione si riferisce a un componente fotoelettrico che usa un complesso di rutenio rappresentato mediante la seguente formula (I): RuL 2 (NCS) 2 Am (I) in cui L, A ed m sono definiti come per la specifica. Tale complesso di rutenio secondo la presente invenzione la è idoneo per una cella solare sensibilizzata con coloranti (DSSC). Pertanto, le caratteristiche fotoelettriche della DSSC della presente invenzione possono essere migliorate.

Complex of ruthenium and photoelectric member whom the same one uses.

La presente invenzione si riferisce a un complesso di rutenio rappresentato mediante la seguente formula (I): RuL 2 (NCS) 2 A m (I) in cui L, A ed m sono definiti come per la specifica, e a un componente fotoelettrico che usa lo stesso. Il complesso di rutenio della presente invenzione può essere usato per una cella solare sensibilizzata con coloranti (DSSC). Pertanto, le caratteristiche fotoelettriche della DSSC prodotta con il complesso di rutenio della presente invenzione possono essere migliorate.

Solar cell with ruthenium complex

La presente invenzione si riferisce a un componente fotoelettrico che usa un complesso di rutenio rappresentato mediante la seguente formula (I): RuL 2 (NCS) 2 Am (I) in cui L, A ed m sono definiti come per la specifica. Tale complesso di rutenio può essere usato per una cella solare sensibilizzata con coloranti (DSSC) della presente invenzione. Pertanto, le caratteristiche fotoelettriche della DSSC della presente invenzione possono essere migliorate.

Divalent-platinum complex containing sterically-hindered aryl group and preparation method and application thereof

The invention discloses an antitumor platinum (II) complex which takes a chiral trans-1, 2-cyclohexanediamine derivative containing a sterically-hindered aryl group as a ligand. The antitumor platinum (II) complex has a structural formula I or II, wherein in the structural formula I, X is H, OCH3 or F and is in the ortho, meta or para position of N-methylene in a benzene ring, in the structural formula II, X is H, OCH3 or F and is in the ortho, meta or para position of N-methylene in a benzene ring, Z is oxalate, malonate, 1, 1-cyclobutyl diacid radical or 3-hydroxy-1, 1-cyclobutyl diacid radical. Two chiral carbon atoms in the trans-1, 2-cyclohexanediamine group have the same three-dimensional configuration and are both in the R or S configuration. The invention also discloses a preparation method of the platinum complex and an application of the platinum complex to the preparation of an anti-tumor medicament.

Sulfonylamides and carboxamides ligands and their transition metal complexes useful for the asymmetric syntheses of chiral secondary alcohols from ketones

La présente invention a pour objet principal de nouveaux dérivés diaminés ou analogues de formule générale I particulièrement utiles, sous leur forme optiquement active, à titre de ligand de complexes métalliques. La présente invention vise également ces complexes, leur procédé de préparation et leur utilisation en synthèse organique asymétrique et notamment pour l'hydrogénation énantiosélective de dérivés cétoniques.

METAL COMPLEX AND ORGANIC SOLAR CELL COMPRISING SAME

The present invention provides a metal complex, which comprises a structure represented by chemical formula 1, and an organic solar cell including the same. COPYRIGHT KIPO 2016 ...

Metal complexes

The present invention describes novel metal complexes. Compounds of this type can be employed as functional materials in a number of different applications which can be ascribed to the electronics industry in the broadest sense. The compounds according to the invention are described by the formulae (1) and (1a).

High nucleation density organometallic compounds

This invention relates to high nucleation density organometallic ruthenium compounds. This invention also relates to a process for producing a high nucleation density organometallic ruthenium compound comprising reacting a bis(substituted-pentadienyl)ruthenium compound with a substituted cyclopentadiene compound under reaction conditions sufficient to produce said high nucleation density organometallic ruthenium compound. This invention further relates to a method for producing a film, coating or powder by decomposing a high nucleation density organometallic ruthenium compound precursor, thereby producing the film, coating or powder.

Raw material for chemical vapor deposition comprising hetero dinuclear complex, and chemical vapor deposition method using the raw material for chemical vapor deposition

Platinum complexes

Method for producing high-purity organoiridium compounds

The present invention relates to a process for preparing highly pure tris-ortho-metallated organoiridium compounds and such pure organometallic compounds which may find use as coloring components in the near future as functional components (=functional materials) in a series of different types of applications which can be classed within the electronics industry in the widest sense.

LIGHT EMITTING DEVICE

Ring R1C to Ring R4C represent an aromatic hydrocarbon ring, RC represents a carbon atom, M represents an iridium atom, n1 and n2 represent integers, E1 and E2 represent a carbon atom, Ring L1 represents an aromatic hetero ring, Ring L2 represents an aromatic hydrocarbon ring, and A1-G1-A2 represents an anionic bidentate ligand.

Lobaplatin Crystal, Preparation Method And Pharmaceutical Application

The present invention relates to new crystals A, B and F of lobaplatin as well as preparation methods therefor and pharmaceutical applications thereof. Lobaplatin crystal A has a melting point Tm.p. of 220±5° C. and is obtained by adding a lobaplatin trihydrate to a suspension crystallization solvent. Lobaplatin crystal B has a melting point Tm.p. of 230±5° C. and is obtained by performing solvent evaporation on a lobaplatin trihydrate or by adding a solvent to a lobaplatin dihydrate, and performing room temperature evaporation or solventing-out crystallization and then drying. Lobaplatin crystal F has a melting point Tm.p. of 229±5° C. and is obtained by adding methanol or ethanol to a lobaplatin dihydrate, stirring at room temperature until solids are dissolved, filtering out insolubles, slowly adding an organic solvent, crystallizing out, separating the crystal and drying the crystal. Compared with the existing lobaplatin and lobaplatin trihydrate, the lobaplatin crystals A, B and F ...

Novel olefin metathesis catalysts

The present invention refers to novel ruthenium- and osmium-based catalysts for olefin metathesis reactions, particularly to catalysts having stereoselective properties. Z-selectivity is obtained by utilising two monoanionic ligands of very different steric requirement. In olefin metathesis reactions these catalysts selectively provide the Z-isomer of disubstituted olefinic products.

CATALYST COMPLEX WITH CARBENE LIGAND

Catalytic complexes including a metal atom having anionic ligands, at least one nucleophilic carbene ligand, and an alkylidene, vinylidene, or allenylidene ligand. The complexes are highly stable to air, moisture and thermal degradation. The complexes are designed to efficiently carry out a variety of olefin metathesis reactions.

СПОСОБ ПОЛУЧЕНИЯ КАРБОКСИЛАТА РУТЕНИЯ (III)

Описывается способ получения раствора карбоксилата рутения (III), который включает взаимодействие оксида рутения (IV) с гидразиновым восстановителем в присутствии карбоновой кислоты и включает первую стадию восстановления рутения (IV) в рутений (III) указанным восстановителем в присутствии карбоновой кислоты и вторую стадию выдержки при повышенной температуре этого рутения (III) в течение длительного периода времени от 8 до 24 ч. Технический результат - получение высокочистых целевых продуктов с высоким выходом. 5 з.п. ф-лы.

ДВОЙНЫЕ МЕТАЛЛОЦЕНОВЫЕ КАТАЛИЗАТОРЫ ДЛЯ ПОЛУЧЕНИЯ БИМОДАЛЬНЫХ ПОЛИМЕРОВ ПОСРЕДСТВОМ ПОЛИМЕРИЗАЦИИ

Данное изобретение относится к каталитическим композициям, способам и полимерам. Описана каталитическая композиция для полимеризации олефинов, содержащая, по меньшей мере, одно первое металлоценовое соединение 4-й группы, включающее в себя мостиковые лиганды η5-циклопентадиенильного типа, в комбинации, по меньшей мере, с одним вторым металлоценом 4-й группы, содержащим лиганды η5-циклопентадиенильного типа, не являющиеся мостиковыми, по меньшей мере, один активатор, выбираемый из активатора-основы, алюмоксанорганического соединения, борорганического или бораторганического соединения, их любой композиции. Технический результат - получение этиленовых полимеров с бимодальным молекулярно-массовым распределением, обладающих хорошей прочностью при ударе, а также хорошим балансом между жесткостью и устойчивостью к медленному распространению трещин. 12 н. и 30 з.п. ф-лы, 3 ил., 2 табл.

СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ, СОЕДИНЕНИЯ, КОМПЛЕКСНЫЙ МЕТАЛЛООРГАНИЧЕСКИЙ КАТАЛИЗАТОР

Настоящее изобретение относится к новым соединениям, пригодным для использования в химической промышленности, формул (I)-(IV)где Е выбран из -BR9R10, -CR11R12OH, -COR11; -SiR11R12R13; -SiR11R12-CH-PR7R8; R9 и R10 представляют собой галоген, гидроксил, алкилокси, арилокси, циклоалкилокси, алкил и циклоалкил; R11, R12 и R13 представляют собой атом водорода, алкил, циклоалкил и арил; R1 и R2 представляют собой алкил, циклоалкил, арил, алкилокси, циклоалкилокси, арилокси, алкиламино, циклоалкиламино, ариламино, металлоценильную группы; R3, R4, R5, R6 представляют собой атом водорода, алкилокси, циклоалкилокси, арилокси, алкиламино, циклоалкиламино и ариламиногруппы; причем алкильная группа как таковая или как часть другого заместителя включает от 1 до 12 атомов углерода, арильная группа как таковая или как часть другого заместителя содержит от 5 до 20 атомов в кольце, циклоалкоксильная группа как таковая или как часть другого заместителя содержит 3, 5 или 6 атомов в кольце; X представляет собой ...

ПАЛЛАДИЕВО-МЕДНЫЕ КАТАЛИЗАТОРЫ ГОМОГЕННОГО СЕЛЕКТИВНОГО ОКИСЛЕНИЯ ТИОЛЬНЫХ ГРУПП, КОМБИНАЦИЯ И КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ТЕРАПЕВТИЧЕСКОГО ВОЗДЕЙСТВИЯ

Изобретение относится к бионеорганической химии, медицинской химии и медицине. Палладиево-медный катализатор гомогенного селективного окисления тиолов сочетает в себе функциональное биядерное тиолатмостиковое координационное соединение палладия(II) и модифицирующий тиолатный комплекс меди(I), имеющий общую формулу SR представляет собой остаток тиолатного лиганда глутатиона или ацетилцистеина, k=2÷14, m≥3k. Также предложены каталитическая комбинация, стимулирующая пролиферативную активность фармакологическая комбинация для усиления терапевтической активности пуринового и (или) пиримидинового основания или ионов лития, фармацевтические композиции, стимулирующие пролиферативную активность и для усиления терапевтической активности указанных оснований или ионов лития, и способы терапевтического воздействия на организм пациента на основе указанного катализатора. Катализатор обладает сниженной токсичностью и может быть использован в фармакологических решениях с лекарственными средствами для терапии ...

КАТАЛИЗАТОРЫ НА ОСНОВЕ ПЕРЕХОДНОГО МЕТАЛЛА 8 ГРУППЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ В РЕАКЦИИ МЕТАТЕЗИСА

Лиганд для получения комплекса переходного металла, способ его получения и способ получения комплекса переходного металла с использованием лиганда

БИМЕТАЛЛИЧЕСКИЕ КОМПЛЕКСЫ И ИХ ПРИМЕНЕНИЕ В ПОЛУЧЕНИИ ДИАРИЛКАРБОНАТОВ

... 1. Соединение с формулой (3)причем R означает водород, фтор, хлор, нитрогруппу, алкиловый остаток с 1-22 атомами углерода, или ариловый остаток с 6-22 атомами углерода,Hal означает хлорид, бромид или иодид, алкоголят или слабо координированный анион, иMозначает медь, марганец или кобальт.2. Способ получения соединений формулы 3 путем гидрирования нитрогрупп соединения формулы 4а с образованием соединений формулы 4b, последующей реакцией с фендионами формулы 5с образованием лигандов формулы 6и комплексированием с соединением формулы 7,,причем Hal имеет приведенное выше значение, a L означает при необходимости присутствующий лиганд.3. Соединения общей формулы 4а и 4b,причем R и Мимеют приведенное выше значение.4. Применение одного или нескольких биметаллических соединений формулы 3 по п.1 в качестве катализатора.5. Применение одного или нескольких биметаллических соединений формулы 3 по п.1 для окислительного карбонилирования ароматических гидроксисоединений до диарилкарбонатов.6. Диарилкарбонаты ...

Übergangsmetallverbindungen, Katalysatorkomponenten und Katalysatoren für die Olefinpolymerisation und ein Verfahren zur Herstellung von Polyolefinen

Neue Tantal- und Niob-Verbindungen

Die vorliegende Erfindung betrifft spezielle, neue Tantal- und Niobverbindungen, die als Ausgangsgröße für die Herstellung von Chemical Vapour Deposition(CVD)-Precusoren dienen können.

Verfahren zur Herstellung heteroleptischer, ortho-metallierter Organometall-Verbindungen

Die vorliegende Erfindung beschreibt ein Verfahren zur Herstellung von hochreinen, heteroleptischen, ortho-metallierten Organometall-Verbindungen, die als funktionelle Materialien in einer Reihe von verschiedenartigen Anwendungen, die im weitesten Sinne der Elektronikindustrie zugerechnet werden können, Einsatz als farbgebende Komponenten finden können. Dabei verwendet man als Verfahren die Spaltung eines verbrückten Metall-Dimers mit metallorganischen Substanzen. Dadurch sind insbesondere auch dihalogenierte Komplexe zugänglich, die als Monomere für Polymerisationen genutzt werden können.

Dye for dye-sensitized solar cells, method of preparing the same, and solar cell including the dye

A dye for dye-sensitized solar cells includes an organometallic complex represented by M(L) p X 2 :(Z) q . In the organometallic complex, M is a Group 8 through Group 10 metallic element, L is a bidentate ligand, X is a co-ligand, and Z is a counter-ion. The ratio of the bidentate ligand (L) to the counter-ion (Z) is about 1.1 to about 1.4. A method of preparing an exemplary dye includes mixing the organometallic complex with tetrabutylammonium thiocyanate and tetrabutylammonium hydroxide to prepare a solution, and purifying the solution at a pH of about 3.8 to about 4.1. A dye-sensitized solar cell includes a first electrode with a light absorbing layer, a second electrode and an electrolyte between the first and second electrodes. The light absorbing layer includes the dye.

Synthesis of terminal alkenes from internal alkenes and ethylene via olefin metathesis

This invention relates generally to olefin metathesis, and more particularly relates to the synthesis of terminal alkenes from internal alkenes using a cross-metathesis reaction catalyzed by a selected olefin metathesis catalyst. In one embodiment of the invention, for example, a method is provided for synthesizing a terminal olefin, the method comprising contacting an olefinic substrate comprised of at least one internal olefin with ethylene, in the presence of a metathesis catalyst, wherein the catalyst is present in an amount that is less than about 1000 ppm relative to the olefinic substrate, and wherein the metathesis catalyst has the structure of formula (II) wherein the various substituents are as defined herein. The invention has utility, for example, in the fields of catalysis, organic synthesis, and industrial chemistry.

Heteroleptic, dual tridentate ru(ii) complexes as sensitizers for dye-sensitized solar cells

Photosensitizers having a formula of RuL 1 L 2 (1) are provided, wherein Ru is ruthenium; L 1 and L 2 are heterocyclic tridentate ligands. L 1 has a formula of (2), and L 2 has a formula of G 1 G 2 G 3 (3), wherein G 1 and G 3 are selected from the group consisting of formulae (4) to (7), and G 2 is selected from the group consisting of formulae (7) and (8). The above-mentioned photosensitizers are suitable to be used as sensitizers for fabrication of high efficiency dye-sensitized solar cells.

Nitrogen-Containing Ligands And Their Use In Atomic Layer Deposition Methods

Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising nitrogen-containing ligands are provided. Also provided are nitrogen-containing ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.

Electrochemical affinity biosensor system and methods

The present invention provides novel osmium-based electrochemical species for the detection of wide variety of analytes using immunological techniques. The present invention also provides diagnostic kits and test sensors supporting electrode structures that can be used with the osmium-based electrochemical species. The test sensor can be fabricated to support interdigitated arrays of electrodes that have been designed to provide amplification of the electrical signal amplification desired to analyze analytes that may be present at low concentrations.

Antiglare and antiseptic coating material and touchscreen coated with the same

An antiglare and antiseptic coating material comprises a nanometric spherical polymer molecule having the formula (I): wherein R1 could be halogens, hydrogen, alkyl groups, alkoxy groups, the hydroxyl group, alkenyl groups, alkynyl groups, acyl groups, aryl groups, carboxyl groups, alkoxycarbonyl groups, or aryloxycarboxyl groups, and wherein R2 could be amino groups, thiol groups, phosphino groups, acid radicals, basic groups, alcohol groups, or alkyl groups, and wherein M's are identical metal atoms or different metal atoms which could be zirconium, copper, titanium, gold, platinum, or zinc. The antiglare and antiseptic coating material is spread on a conductive layer or an outer cover layer of a touchscreen to provide a durable, weather-resistant antiglare and antiseptic coating for the touchscreen. Further, the coating can dim fingerprints on the touchscreen.

Blue-light-emitting iridium complex, iridium complex monomer, phosphorus polymer, and organic electroluminescence device using same

Provided are a blue-light-emitting iridium complex, an iridium complex monomer, a phosphorescent polymer, and an organic electroluminescent device using same. The blue-light-emitting iridium complex contains a ligand having a low electron density structure, such as triazole or tetrazole. The iridium complex monomer containing a ligand having a polymerizable vinyl group produces a blue phosphorescent polymer through the polymerization with carbazole derivatives. The organic electroluminescent device comprises a first electrode, a second electrode, and a light-emitting layer interposed between the first electrode and the second electrode, wherein the light-emitting layer contains the above-described iridium complex or polymer containing the iridium complex.

Ruthenium (ii) catalysts for use in stereoselective cyclopropanations

Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N′-bis(3,5-di-t-butyl-salicylidene) and RuCl 2 (p-cymene)] 2 .

Compositions comprising functionalized carbon-based nanostructures and related methods

The present invention generally relates to compositions comprising and methods for forming functionalized carbon-based nanostructures.

Neutral mixed ligand transition metal complexes as active materials in solid-state organic photovoltaic devices

The present invention describes novel “black absorbers” comprising mixed ligand metal-organic complexes to be used in OPVs. The invention describes three representative metal-organic dyes that exhibit strong absorptions spanning the entire UV/Vis portion of the solar light and, in the some cases, well within the NIR. The invention further describes the fabrication of an OPV device by co-doping P1 in a standard polymer/fullerene matrix commonly used in a bulk heterojunction device structure.

Material selecting method upon purifying iridium complex by sublimation

Provided is a material selecting method used upon purifying an iridium complex by sublimation which includes: selecting an iridium complex having a specific structure and having a rate of weight loss of 45% or greater when heated to 500° C. at a heating rate of 2° C./min under the degree of vacuum of from 1×10 −3 Pa to 1×10 −1 Pa; and carrying out sublimation purification.

Heteroleptic carbene complexes and the use thereof in organic electronics

The present invention relates to heteroleptic complexes comprising a phenylimidazole or phenyltriazole unit bonded via a carbene bond to a central metal atom, and phenylimidazole ligands attached via a nitrogen-metal bond to the central atom, to OLEDs which comprise such heteroleptic complexes, to light-emitting layers comprising at least one such heteroleptic complex, to a device selected from the group consisting of illuminating elements, stationary visual display units and mobile visual display units comprising such an OLED, to the use of such a heteroleptic complex in OLEDs, for example as emitter, matrix material, charge transport material and/or charge blocker.

Composite material, light-emitting element, light-emitting device, electronic device, and lighting device

A composite material which includes an organic compound and an inorganic compound and has a high carrier-transport property is provided. A composite material having a good property of carrier injection into an organic compound is provided. A composite material in which light absorption due to charge-transfer interaction is unlikely to occur is provided. A composite material having a high visible-light-transmitting property is provided. A composite material including a hydrocarbon compound and an inorganic compound exhibiting an electron-accepting property with respect to the hydrocarbon compound is provided. The hydrocarbon compound has a substituent bonded to a naphthalene skeleton, a phenanthrene skeleton, or a triphenylene skeleton and has a molecular weight of 350 to 2000, and the substituent has one or more rings selected from a benzene ring, a naphthalene ring, a phenanthrene ring, and a triphenylene ring.

Catalytic complex for olefin metathesis reactions, process for the preparation thereof and use thereof

The present invention relates to a catalytic complex for olefin metathesis reactions, to a process for its preparation and to its use in olefin metathesis reactions, particularly in ring opening metathesis polymerisation (ROMP) reactions.

Novel iridium complex, organic light-emitting device, and image display apparatus

There is provided a novel iridium complex having a small half-width of an emission spectrum and an organic light-emitting device that contains the iridium complex. There is provided a novel iridium complex that has a phenyl ring and an imidazole ring as ligands and that has a basic skeleton in which the phenyl ring is bonded to a triazine ring.

Material for organic electroluminescence devices and organic electroluminescence device using the material

A material for organic electroluminescence devices comprising a compound in which a heterocyclic group having nitrogen is bonded to an arylcarbazolyl group or a carbazolylalkylene group and an organic electroluminescence device comprising an anode, a cathode and an organic thin film layer comprising at least one layer and disposed between the anode and the cathode, wherein at least one layer in the organic thin film layer comprises the material for organic electroluminescence devices described above. The material can provide an organic electroluminescence device emitting bluish light with a high purity of color. The organic electroluminescence device uses the material.

Palladium precursor composition

A palladium precursor composition contains a palladium salt and an organoamine. The composition permits the use of solution processing methods to form palladium layers.

Light-emitting material comprising orthometalated iridium complex, light-emitting device, high efficiency red light-emitting device, and novel iridium complex

A light-emitting material comprises iridium and at least one ligand represented by the following formula: wherein R 11 and R 12 each represents an alkyl group, an aryl group, a heteroaryl group, an alkoxy group, a cyano group or a cyclic structure obtained by connection of one of a plurality of R 11 s to another of said plurality of R 11 s, or one of a plurality of R 12 s to another of said plurality of R 12 s, or one of the R 11 s to one of the R 12 s; m 1 represents an integer from 0 to 4; m 2 represents an integer from 0 to 6.

Phosphorescent material, their preparations and applications

The subject invention is directed to tetradentate bis-(NHC carbenes) alkylene ligand Pt(II) complexes, tetradentate bis-(NHC carbenes) alkylene ligands, and its ligand precursors, for preparation of the Pt(II) complexes. The Pt(II) complexes show a deep blue emission with an improved quantum efficiency and can be used for fabrication of OLEDs with an electroluminescence layer that comprise the bis-(NHC carbenes) alkylene ligand Pt(II) complexes.

Light-emitting organic platinum complex, light-emitting material containing this complex and functional device

The present invention provides a light-emitting organic platinum complex, a light-emitting material containing this complex, and a functional device containing this complex. The light-emitting organic platinum complex is represented by any one of the following structural formulae: where: Z represents either —(CH 2 ) n — or —CH 2 (CH 2 OCH 2 ) m CH 2 —, where n represents 7 to 14, and m represents 3 to 4; A represents either an optionally condensed aromatic hydrocarbon ring or an optionally condensed heteroaromatic ring; R is a substituent group for A and represents H (unless n of Z in the structural formula (1) is 7 to 13), a halogen, a C 1 -C 6 alkyl group, a C 1 -C 6 alkenyl group, a C 1 -C 6 alkynyl group, a C 1 -C 6 alkoxy group or the like.

Compositions and methods for the treatment of cancer

The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand.

Organometallic compound and organic electroluminescence device employing the same

Organometallic compounds and organic electroluminescence devices employing the same are provided. The organometallic compound has a chemical structure represented below: wherein, X is C—H or N, Y is CH 2 or NH; R 1 is H, or C 1-8 alkyl; and A 1 is acetylacetone ligand, acetylacetone with phenyl group ligand, or derivatives thereof.

Ruthenium based complexes

The present invention relates to the field of one step process for the preparation of monomeric or dimeric [Ru(di-ene) (OOCR) 2 ] n complexes from [(diene)Ru Cl 2 ] n , as well as a new class of [Ru(diene)(OOCR) 2 ] mn complexes and their use to prepare [Ru(PP)(OOCR) 2 ] complexes, which are good catalysts.

Methods of nanoassembly of a fractal polymer and materials formed thereby

The invention relates to the formation of synthesized fractal constructs and the methods of chemical self-assembly for the preparation of a non-dendritic, nano-scale, fractal constructs or molecules. More particularly, the invention relates to fractal constructs formed by molecular self-assembly, to create synthetic, nanometer-scale fractal shapes. In an embodiment, a nanoscale Sierpinski hexagonal gasket is formed. This non-dendritic, perfectly self-similar fractal macromolecule is comprised of bisterpyridine building blocks that are bound together by coordination to (36) Ru and (6) Fe ions to form a nearly planar array of increasingly larger hexagons around a hollow center.

Complexes of Ruthenium, Method of Production Thereof And Use Thereof As (Pre)Catalysts of the Metathesis Reaction

The present invention provides ruthenium complexes of the formula 111-. (canceled)13. The complex of claim 12 , wherein X and X′ are chlorine.14. The complex of claim 12 , wherein Ris hydrogen.15. The complex of claim 12 , wherein A is nitrogen.16. The complex of claim 12 , wherein A is carbon with an Rgroup.17. The method for preparing the ruthenium complex of which comprises reacting 8-ethenylquinoline with a Ru carbene catalyst.19. The method of claim 17 , wherein the Ru carbene catalyst comprises an indenylidene residue claim 17 ,20. The method according to claim 17 , wherein the reaction is conducted in the presence of a copper(I) salt.21. The method according to claim 20 , wherein the copper(I) salt is copper(I) chloride.22. The method according to claim 17 , wherein the reaction is performed in a chlorinated solvent claim 17 , an aliphatic solvent claim 17 , a cycloaliphatic solvent or an aromatic hydrocarbon solvent claim 17 , or mixtures thereof.24. An improved process for ring closing metathesis (RCM) claim 12 , wherein the improvement comprise the use of the ruthenium complex of as an initiator or (pre)catalyst.25. An improved process for ring-opening metathesis polymerization (ROMP) claim 12 , wherein the improvement comprises the use of the ruthenium complex of as an initiator or (pre)catalyst.26. An improved process for metathesis of “alkene-alkyne” (ene-yne) type claim 12 , wherein the improvement comprises the use of the ruthenium complex of as an initiator or (pre)catalyst. This application is a continuation application of U.S. patent application Ser. No. 12/303,615, filed Apr. 3, 2009, which in turn is a national stage application of PCT Application No. EP2007/004901, filed Jun. 1, 2007. The disclosures of the above-referenced applications are hereby incorporated by reference into the present disclosure.The invention relates to novel metal complexes with formula 1, whereCompounds of formula 1 occur as two isomers: with formula 1a, in which atoms X ...

6,13-DIHALOGEN-5,14-DIHYDROPENTACENE DERIVATIVE AND METHOD FOR PRODUCING 6,13-SUBSTITUTED-5,14-DIHYDROPENTACENE DERIVATIVE USING SAME

The present invention provides a 6,13-dihalogen-5,14-dihydropentacene derivative and a method for production thereof. Compounds (b) and (c) are reacted through cross-coupling reaction in the presence of a metal compound and a lithiating agent to synthesize compound (d), which is then halogenated to thereby obtain a 6,13-dihalogen-5,14-dihydropentacene derivative (compound (e)). 2. The derivative according to claim 1 , wherein Xand Xare each an iodine atom.3. The derivative according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand R claim 1 , which may be the same or different claim 1 , are each independently a hydrogen atom; an optionally substituted C-Calkyl group; an optionally substituted C-Caryl group or an optionally substituted silyl group.4. The derivative according to any claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rare each a hydrogen atom.6. The method according to claim 5 , wherein the organometallic compound is selected from the group consisting of an organolithium compound claim 5 , an organomagnesium compound claim 5 , an organoaluminum compound claim 5 , an organozinc compound claim 5 , an organoboron compound and an organosilyl compound.8. The method according to any claim 5 , wherein the transition metal catalyst comprises a nickel complex or a palladium complex.9. The method according to claim 5 , wherein Aand A claim 5 , which may be the same or different claim 5 , are each independently an optionally substituted C-Calkyl group claim 5 , an optionally substituted C-Calkenyl group claim 5 , an optionally substituted C-Calkynyl group claim 5 , an optionally substituted C-Caryl group or an optionally substituted heteroaryl group.10. The method according to claim 5 , wherein Xand Xare each an iodine atom.11. The method according to claim 5 , wherein R claim 5 , R claim 5 , R claim 5 , R claim 5 , R claim ...

METAL COMPLEXES

The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, com-prising these metal complexes. M(L)n(L′)m (formula 1), where the compound of the general formula (1) contains a moiety M(L)n of the formula (2). 117-. (canceled)19. The compound according to claim 18 , wherein it is uncharged.20. The compound according to claim 18 , wherein M is selected from the group consisting of chromium claim 18 , molybdenum claim 18 , tungsten claim 18 , rhenium claim 18 , ruthenium claim 18 , osmium claim 18 , rhodium claim 18 , iridium claim 18 , nickel claim 18 , palladium claim 18 , platinum claim 18 , copper claim 18 , silver and gold.21. The compound according to claim 18 , wherein claim 18 , in the ligand L claim 18 , one claim 18 , two claim 18 , three or four groups X stand for N.22. The compound according to claim 18 , wherein claim 18 , in the ligand L claim 18 , one claim 18 , two claim 18 , or three groups X claim 18 , stand for N.23. The compound according to claim 18 , wherein claim 18 , for each X which stands for N claim 18 , at least one X which is adjacent to this N stands for CR.26. The compound according to claim 18 , wherein claim 18 , if further radicals R are bonded in the moiety of the formula (2) in addition to the radicals R claim 18 , these radicals R are selected on each occurrence claim 18 , identically or differently claim 18 , from H claim 18 , D claim 18 , F claim 18 , Br claim 18 , I claim 18 , N(R) claim 18 , CN claim 18 , Si(R) claim 18 , B(OR) claim 18 , C(═O)R claim 18 , a straight-chain alkyl group having 1 to 10 C atoms or an alkenyl group having 2 to 10 C atoms or a branched or cyclic alkyl group having 3 to 10 C atoms claim 18 , each of which is optionally substituted by one or more radicals R claim 18 , where one or more H atoms is optionally replaced by D or F claim 18 , or an aromatic or heteroaromatic ring system having 5 to 30 aromatic ring atoms claim 18 , which may in ...

ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS

Disclosed herein are phosphorescent materials comprising a complex of a metal atom M selected from Ir, Pt, Rh, Pd, Ru and Os and at least one ligand L, wherein the ligand L is represented by formula (1). Also disclosed are organic electroluminescent devices including such phosphorescent materials. 2. The device of claim 1 , wherein the substituents in rings A and B of the phosphorescent material are independently selected from the group consisting of:halogen, cyano, amide, imine, imide, amidine, amine, nitro, hydroxy, ether, carbonyl, carboxy, carbonate, carbamate, phosphine, phosphate, phosphonate, sulphide, sulphone, sulphoxide, alkenyl, alkynyl, silyl, and substituents containing a functional group that can be polymerised or a polymer chain, and [{'sub': '2', 'one or more of the carbon atoms in the alkyl, aryl or alkyl-aryl may be replaced with an atom or group selected from the group consisting of: —O—, —S—, —CO—, —CO—, —CH═CH—, —C≡C—, —NH—, —CONH—, —C═N—, —Si— and —P—, wherein the atoms —Si— and —P— contain substituents for neutrality based on their valency,'}, 'the substituents on the alkyl, aryl or alkyl-aryl are selected from the group consisting of: halogen, cyano, amide, imine, imide, amidine, amine, nitro, hydroxy, ether, carbonyl, carboxy, carbonate, carbamate, phosphine, phosphate, phosphonate, sulphide, sulphone, sulphoxide, alkenyl, alkynyl, silyl and substituents containing a functional group that can be polymerised or a polymer chain, and', 'the alkyl, aryl or alkyl-aryl may additionally be connected to the tether Q, or the alkyl, aryl or alkyl-aryl may be attached via two points to its core ring (A or B) to form a fused ring or ring system., 'substituted or unsubstituted alkyl, substituted or unsubstituted aryl and substituted or unsubstituted alkyl-aryl, wherein3. The device of claim 1 , wherein the phosphorescent material comprises 1 claim 1 , 2 or 3 ligands L of formula (1) claim 1 , and 0 claim 1 , 1 or 2 bidentate ligands L′ of a different ...

METAL COMPLEX DYE, PHOTOELECTRIC CONVERSION ELEMENT AND DYE-SENSITIZED SOLAR CELL

A metal complex dye, containing a ligand LL1 having a structure represented by Formula (I): 2. The metal complex dye according to claim 1 , which is represented by Formula (XIII) or Formula (XV).3. The metal complex dye according to claim 1 , which is represented by Formula (XIII).4. The metal complex dye according to claim 1 , wherein Rand Rin Formula (XIII) each are an alkynyl group having 5 to 15 carbon atoms.5. The metal complex dye according to claim 1 , wherein Rand Rin Formula (XIII) each are a hydrogen atom.6. The metal complex dye according to claim 1 , wherein Rand Rin Formula (XIII) each are a hydrogen atom or an alkyl group.7. The metal complex dye according to claim 1 , wherein Rand Rin Formula (XIV) each are a branched or straight-chain alkyl group having 4 to 10 carbon atoms.8. The metal complex dye according to claim 1 , wherein Rand Rin Formula (XV) each are a branched or straight-chain alkyl group having 4 to 10 carbon atoms.9. The metal complex dye according to claim 1 , wherein Rto Rand Rto Rin Formula (XV) each are a hydrogen atom.10. The metal complex dye according to claim 1 , wherein Z is isothiocyanate claim 1 , isocyanate or isoselenocyanate.11. A photoelectric conversion element claim 1 , comprising semiconductor fine particles sensitized with the metal complex dye according to .12. A photoelectric conversion element claim 1 , comprising semiconductor fine particles sensitized with a plurality of dyes claim 1 , at least one of which is the metal complex dye according to .13. The photoelectric conversion element according to claim 12 , at least one of the plurality of dyes has a maximum absorption wavelength of 600 nm or more on the longest wavelength side in THF/water (=6:4 claim 12 , trifluoroacetic acid 0.1 v/v %) solution.15. A dye-sensitized solar cell claim 11 , comprising the photoelectric conversion element according to .16. A dye-sensitized solar cell claim 12 , comprising the photoelectric conversion element according to .17. A ...

Emissive compounds for organic light-emitting diodes

Disclosed herein are compounds comprising an optionally substituted (2-phenylpyridinato-N,C2′)(2,4-pentanedionato)Pt(II). Some embodiments provide a light-emitting device, comprising: an anode layer; a cathode layer; and a light-emitting layer positioned between, and electrically connected to, the anode layer and the cathode layer, wherein the light-emitting layer comprises a compound disclosed herein.

Phosphorescent Iridium Metal Complex, Light-Emitting Element, Light-Emitting Device, Electronic Appliance, and Lighting Device

Provided is a light-emitting element including a phosphorescent iridium metal complex that emits phosphorescence in a yellow green to orange wavelength range, and has high emission efficiency and reliability. Thus, further provided is the phosphorescent iridium metal complex that emits phosphorescence in the yellow green to orange wavelength range. Further provided are a light-emitting device, an electronic appliance, and a lighting device each of which includes the above light-emitting element. The light-emitting element includes an EL layer between a pair of electrodes, and the EL layer contains a phosphorescent iridium metal complex where nitrogen at the 3-position of a pyrimidine ring having an aryl group bonded to the 4-position is coordinated to a metal, a substituent having a carbazole skeleton is bonded to the 6-position of the pyrimidine ring, and the aryl group bonded to the 4-position of the pyrimidine ring is ortho-metalated by being bonded to the metal. 1. A light-emitting element comprising an EL layer between a pair of electrodes , the EL layer comprising a phosphorescent iridium metal complex ,wherein in the phosphorescent iridium metal complex:nitrogen at a 3-position of a pyrimidine ring having an aryl group bonded to a 4-position of the pyrimidine ring is coordinated to iridium,a substituent having a carbazole skeleton is bonded to a 6-position of the pyrimidine ring, andthe aryl group bonded to the 4-position of the pyrimidine ring is ortho-metalated by being bonded to the iridium.5. A light-emitting device comprising the light-emitting element according to .6. An electronic appliance comprising the light-emitting element according to .7. A lighting device comprising the light-emitting element according to .8. A light-emitting element comprising an EL layer between a pair of electrodes claim 1 , the EL layer comprising a phosphorescent iridium metal complex claim 1 ,wherein in the phosphorescent iridium metal complex:nitrogen at a 1-position of a ...

Metalloinsertor complexes targeted to dna mismatches

A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.

Transition metal complexes of amino acids and related ligands and their use as catalysts, anti-microbials, and anti-cancer agents

The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the present invention provide transition metal complexes of amino acids. Transition metal complexes of embodiments of the invention according to Categories I, II, III, and/or IV may be used as antimicrobial, anti-malarial, and anti-cancer agents, as well as catalysts in chemical reactions. Such compounds of the invention are particularly useful for combating multi-drug resistance against a broad range of microbials (such as MRSA and mycobacteria), including gram positive and gram negative bacteria, as well as can be used as anti-cancer agents against bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer, to name a few.

PROCESS

The present invention provides a process for the preparation of Pd(dba).CHClcomprising the steps of: (a) reacting a Pd(II) complex with an alkali metal halide in at least one alcohol solvent; and (b) reacting the product of step (a) with a mixture comprising dibenzylideneacetone, chloroform and an inorganic base to form Pd(dba).CHCl. 1. A process for the preparation of Pd(dba).CHClcomprising the steps of:(a) reacting a Pd(II) complex with an alkali metal halide in at least one alcohol solvent; and{'sub': 2', '3', '3, '(b) reacting the product of step (a) with a mixture comprising dibenzylideneacetone, chloroform and an inorganic base to form Pd(dba).CHCl.'}2. A process according to claim 1 , wherein the Pd(II) complex is selected from the group consisting of Pd(Hal) claim 1 , Pd(diolefin)(Hal)and Pd(CHCN)(Hal).3. A process according to claim 1 , wherein the alkali metal halide is selected from the group consisting of lithium halide claim 1 , sodium halide claim 1 , potassium halide and a combination thereof.4. A process according to claim 3 , wherein the alkali metal halide is lithium chloride.5. A process according to claim 1 , wherein the at least one alcohol solvent has a boiling point below 180° C. at atmospheric pressure.6. A process according to claim 1 , wherein step (a) is carried out at a temperature from about 20° C. to about 50° C.7. A process according to claim 1 , wherein the product of step (a) is recovered prior to step (b) or the product of step (a) is used directly in step (b).8. A process according to claim 1 , wherein the molar ratio of Pd(II) complex:dibenzylideneacetone is about 2:3.05 to about 2:3.25.9. A process according to claim 8 , wherein the molar ratio of Pd(II) complex:dibenzylideneacetone is about 2:3.20.10. A process according to claim 1 , wherein the inorganic base is an alkali metal acetate.11. A process according to claim 1 , wherein the product of step (a) is added to the mixture comprising dibenzylideneacetone claim 1 , ...

IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND

An object of the present invention is to provide a novel iridium complex, and to provide a novel catalyst having excellent performances in terms of enantioselectivity, catalytic activity, and the like. Provided is an iridium complex of the following general formula (1): 111.-. (canceled)12. An iridium complex of the following general formula (1):{'br': None, 'sub': 2', 'm, 'IrHZ(PP)(Q)\u2003\u2003(1)'}wherein Z represents a halogen atom,PP represents a bisphosphine,Q represents an amine, andm represents 1 or 2.13. The iridium complex according to claim 12 , whereinPP in the general formula (1) is an optically active bisphosphine.14. The iridium complex according to claim 13 , wherein {'br': None, 'sup': 1', '2', '3, 'NRRR\u2003\u2003(2)'}, 'Q in the general formula (1) is an amine represented by the following general formula (2){'sup': 1', '2', '3, 'wherein R, Rand Reach independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aryl group which optionally have a substituent.'}19. The production method according to claim 17 , wherein {'br': None, 'sup': 1', '2', '3, 'NRRR\u2003\u2003(2)'}, 'the amine is an amine represented by the following general formula (2){'sup': 1', '2', '3, 'wherein R, Rand Reach independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aryl group which optionally have a substituent.'}21. An asymmetric hydrogenation catalyst comprising the iridium complex according to .23. The production method according to claim 18 , wherein {'br': None, 'sup': 1', '2', '3, 'NRRR\u2003\u2003(2)'}, 'the amine is an amine represented by the following general formula (2){'sup': 1', '2', '3, 'wherein R, Rand Reach independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aryl group which optionally have a substituent.'} The present invention relates to an iridium complex and a method for producing an optically active compound.Synthetic methods based on catalytic ...

PHENYL AND FLUORENYL SUBSTITUTED PHENYL-PYRAZOLE COMPLEXES OF Ir

The invention provides emissive materials and organic light emitting devices using the emissive materials in an emissive layer disposed between and electrically connected to an anode and a cathode. The emissive materials include compounds with the following structure: 2. The compound of claim 1 , wherein n is 3 and m is zero.3. The compound of claim 2 , wherein M is selected from the group consisting of Ir claim 2 , Pt claim 2 , Pd claim 2 , Rh claim 2 , Re claim 2 , Ru claim 2 , Os claim 2 , Tl claim 2 , Pb claim 2 , Bi claim 2 , In claim 2 , Sn claim 2 , Sb claim 2 , Te claim 2 , Au claim 2 , and Ag.4. The compound of claim 3 , wherein M is Ir.5. The compound of claim 4 , wherein R claim 4 , R claim 4 , and Rto Rare H.6. The compound of claim 1 , wherein at least one ligand functions as a phosphorescent emissive ligand in the compound at room temperature and at least one ligand does not function as a phosphorescent emissive ligand in the compound at room temperature;wherein the emissive ligand in the compound at room temperature has a triplet energy corresponding to a wavelength that is at least 80 nm greater than the wavelength corresponding to the triplet energy of the ligand that is not emissive in the compound at room temperature.7. The compound of claim 6 , wherein the emissive ligand has a triplet energy corresponding to a wavelength of 500-520 nm.8. The compound of claim 6 , wherein the emissive ligand has a triplet energy corresponding to a wavelength greater than 590 nm.9. The compound of claim 1 , wherein the ligands are in facial configuration with respect to the coordinating atoms of the ligands.10. An organic light emitting device claim 1 , comprising:an anode;a cathode; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an emissive layer disposed between the anode and the cathode, the emissive layer comprising a compound of .'}11. The device of claim 10 , wherein M is selected from the group consisting of Ir claim 10 , Pt claim 10 , Pd claim 10 , ...

NOVEL ORGANO-PALLADIUM COMPLEXES

The present invention relates generally to novel complexes of palladium or a palladium salt, lipoic acid and a long chain fatty acid, where the palladium is bonded to lipoic acid via both sulfurs and carboxyl group oxygens of lipoic acid, and where the long chain fatty acid is bonded to the palladium via the carboxyl group of the long chain fatty acid. The complexes are useful as cancer chemotherapy agents. 1. A complex of Formula I{'br': None, 'sub': a', 'b', 'c', 'd', 'e, '(Me)(Lipoic acid)(fatty acid)(zinc)(amino acid)\u2003\u2003(Formula I)'}whereinthe Me component is palladium or a palladium salt thereof;the lipoic acid component comprises lipoic acid or a derivative thereof, wherein the lipoic acid component comprises at least two sulfur atoms and at least one carboxyl group;the fatty acid component comprises a hydrocarbon chain of from 2 to twenty carbon atoms wherein at one end of the hydrocarbon chain is a methyl group and at the other end is a carboxyl group;the zinc component, when present, is bonded to a methyl group at one end of the fatty acid,and the amino acid component, when present, is bonded to the zinc component,the palladium is bonded to the lipoic acid component via both sulfur atoms and by the carboxyl group oxygens of the lipoic acid component;the fatty acid is bonded to the palladium via the carboxyl group of the fatty acid;wherein a, b, and c are each 1d is 0 or 1e is 0, 1 or 2and standard potential of the complex is electropositive.2. The complex of claim 1 , wherein the palladium salt is selected from the group consisting of palladium chloride claim 1 , palladium bromide claim 1 , palladium iodide claim 1 , palladium nitrate claim 1 , palladium oxide and palladium sulfide.3. (canceled)4. The complex of claim 1 , wherein the lipoic acid derivative comprises a side group selected from a carboxyl claim 1 , a sulfur claim 1 , an amine or a combination thereof.5. The complex of claim 4 , wherein the lipoic acid derivative is lipoamide:6. The ...

MICROWAVE-ASSISTED SYNTHESIS OF N-HETEROCYCLIC CARBENE TRANSITION METAL COMPLEXES

Microwave heating is used to synthesize NHC-transition metal complexes. Reaction times for the formation of NHC-transition metal complexes is greatly reduced. The speed of the reactions allows for otherwise problematic air handling of reagents. Apparatus for carrying out the reactions is less complex than conventional apparatus and requires less energy to achieve the desired temperatures. Methods utilize salts of NHC's which overcomes the oftentimes difficult preparation of free carbenes for formation of the corresponding transition metal complexes. 2. The method of claim 1 , wherein a) further comprises an organic solvent.3. The method of claim 2 , wherein the N-heterocyclic carbene salt of formula II is combined with the transition metal salt of formula MX claim 2 , a ligand L and a base; wherein:M is Pd, Pt, Ni, Cu, Au, Ag, Ru, Rh or Ir;{'sup': −', '−', '−', '−', '−', '5', '−', '5', '−', '5', '−', '−', '−', '5, 'sub': 2', '2', '4', '5', '6', '4', '6', '1-6', '1-6, 'each X is F, Cl, Br, I, OC(O)R, O(SO)R, O(SO)Ph-R, BF, B(FC)or PF; where Ris Calkyl or perfluoroCalkyl;'}L is an optionally substituted 5-15 membered heteroaryl containing at least one nitrogen, oxygen or sulfur, said 5-15 membered coordinated to M through said at least one nitrogen, oxygen or sulfur; orone of X combines with one of L to form a bidentate monoanionic ligand, where said one of X is the anionic portion of the bidentate monoanionic ligand and L is the neutral coordination portion of the bidentate monoanionic ligand; and{'sup': −', '−', '−', '−', '−', '5', '−', '5', '−', '5', '−', '−', '−', '5, 'sub': 2', '2', '4', '5', '6', '4', '6', '1-6', '1-6, 'Y is F, Cl, Br, I, OC(O)R, O(SO)R, O(SO)Ph-R, BF, B(FC)or PF; where Ris Calkyl or perfluoroCalkyl.'}4. The method of claim 3 , wherein:a is 1;{'sup': 1', '2, 'sub': 1-10', '3-10', '6-10', '7-12, 'each of Rand Ris independently H, Calkyl, Ccycloalkyl, Caryl or Carylalkyl; each optionally substituted;'}{'sup': 3', '4', 'e', 'e', 'a', 'b, 'Rand Rare ...

ORGANO-METALLIC FRAMEWORKS DERIVED FROM CARBENOPHILIC METALS AND METHODS OF MAKING SAME

The disclosure provides organic frameworks comprising increased stability. 1. An organo-metallic framework comprising the general structure M-L-M , wherein M is a framework metal and wherein L is a linking moiety comprising an N-heterocyclic carbene.2. The organo-metallic framework of claim 1 , wherein the linking moiety is metallated prior to reacting with the framework metal.3. (canceled)4. The organo-metallic framework of claim 1 , wherein the framework comprises a covalent organic framework (COF) claim 1 , a zeolitic imidizole framework (ZIF) or a metal organic framework (MOF).5. The organo-metallic framework of claim 1 , wherein the framework metal is selected from the group consisting of Li claim 1 , Na claim 1 , Rb claim 1 , Mg claim 1 , Ca claim 1 , Sr claim 1 , Ba claim 1 , Sc claim 1 , Ti claim 1 , Zr claim 1 , Ta claim 1 , Cr claim 1 , Mo claim 1 , W claim 1 , Mn claim 1 , Fe claim 1 , Ru claim 1 , Os claim 1 , Co claim 1 , Ni claim 1 , Pd claim 1 , Pt claim 1 , Cu claim 1 , Au claim 1 , Zn claim 1 , Al claim 1 , Ga claim 1 , In claim 1 , Si claim 1 , Ge claim 1 , Sn claim 1 , and Bi.6. The organo-metallic framework of claim 1 , wherein the linking moiety comprising the heterocyclic carbene is modified with a modifying metal.7. The organo-metallic framework of claim 6 , wherein the modifying metal is selected from the group consisting of L1 claim 6 , Be claim 6 , Na claim 6 , Mg claim 6 , Al claim 6 , Si claim 6 , K claim 6 , Ca claim 6 , Ti claim 6 , V claim 6 , Cr claim 6 , Mn claim 6 , Fe claim 6 , Co claim 6 , Ni claim 6 , Cu claim 6 , Zn claim 6 , Ga claim 6 , Ge claim 6 , Sr claim 6 , Y claim 6 , Zr claim 6 , Nb claim 6 , Mo claim 6 , Ru claim 6 , Rh claim 6 , Pd claim 6 , Ag claim 6 , Sn claim 6 , Te claim 6 , Ba claim 6 , Hf claim 6 , Ta claim 6 , W claim 6 , Re claim 6 , Os claim 6 , Ir claim 6 , Pt claim 6 , Au claim 6 , Hg claim 6 , Sm claim 6 , Eu claim 6 , and Yb8. The organo-metallic framework of claim 6 , wherein the modifying metal extends ...

PROCESS FOR PREPARATION OF 1,2-DIAMINO-CYCLOHEXANE-PLATINUM (II) COMPLEXES

The present invention is directed to a manufacturing process for 1,2-diamino-cyclohexane-platinum(II) complexes, specifically to a manufacturing process for oxaliplatin. 2. A process for preparing oxaliplatin (cis-oxalato-(trans-l-1 ,2-cyclohexanediamine)-platinum-II) of the structural formula I comprising the following steps:{'sub': 2', '4, 'a) reacting potassium tetrachloroplatinate (II) [KPtCl] with trans-l-1,2-cyclohexanediamine to obtain the dichloro-[(trans-l -1,2-cyclohexane-diamine-N,N′]-platinum(II) complex,'}{'sub': 2', '4, 'b) reacting the dichloro-[(trans-l-1,2-cyclohexandiamine-N,N′]-platinum(II) complex with silver sulfate (AgSO) to obtain [(trans-l-1,2-cyclohexandiamine-N,N′]-platinum(II) -diaquo-sulfate and silver chloride (AgCl),'}{'sub': 2', '2', '2', '4', '4, 'c1) reacting the [(trans-l-1,2-cyclohexandiamine-N,N′]-platinum(II)-diaquo -sulfate with equimolar portions of barium hydroxide (Ba(OH)) and oxalic acid (HCO) to obtain oxaliplatin(cis-oxalato-(trans-l-1,2-cyclohexane-diamine) -platinum-II) and barium sulfate (BaSO).'}3. The process according to claim 1 , further comprising a step b′) for the removal of silver chloride.4. The process according to claim 1 , further comprising a step c′) for the removal of barium sulfate.5. The process according to claim 1 , further comprising a step d) for the isolation and/or purification of the oxaliplatin product.6. The process according to claim 1 , wherein after addition of barium oxalate (BaCO) the pH is adjusted to the range of pH=4-7.7. The process according to claim 2 , wherein after addition of oxalic acid (HCO) and barium hydroxide (Ba(OH)) the pH is adjusted to the range of pH=4-7.8. The process according to claim 2 , wherein in step c1) the barium oxalate (BaCO) is formed in situ in the reaction mixture.9. The process according to claim 3 , wherein the removal of silver chloride (AgCl) in step b′) is performed by filtration.10. The process according to claim 5 , wherein the isolation and/or ...

Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device

As a novel substance having a novel skeleton, a novel organometallic complex that can emit phosphorescence in the green to red wavelength region and has high emission efficiency and a high yield of synthesis is provided. One embodiment of the present invention is an organometallic complex in which a diketone having a five-membered or six-membered alicyclic structure composed of carbon and hydrogen is a ligand. 2. The organometallic complex according to claim 1 ,wherein the aromatic ligand is a nitrogen-containing heteroaromatic ring derivative substituted by an aryl group or a nitrogen-containing heterocyclic carbene derivative substituted by an aryl group, andwherein a site of substitution of the aryl group is a carbon atom adjacent to a nitrogen atom of the nitrogen-containing heteroaromatic ring or a nitrogen atom adjacent to a carbene carbon atom.6. A light-emitting element comprising the organometallic complex according to .7. A light-emitting device comprising the light-emitting element according to .8. An electronic device comprising the light-emitting device according to .9. A lighting device comprising the light-emitting device according to .11. A light-emitting element comprising the organometallic complex according to .12. A light-emitting device comprising the light-emitting element according to .13. An electronic device comprising the light-emitting device according to .14. A lighting device comprising the light-emitting device according to .16. A light-emitting element comprising the organometallic complex according to .17. A light-emitting device comprising the light-emitting element according to .18. An electronic device comprising the light-emitting device according to .19. A lighting device comprising the light-emitting device according to . 1. Field of the InventionOne embodiment of the present invention relates to an organometallic complex. In particular, one embodiment of the present invention relates to an organometallic complex that is capable ...

Tridentate Platinum (II) Complexes

A platinum (II) complex of general formula (II), 17-. (canceled)9. (canceled)10. The complex of claim 8 , wherein Ar3 is an anion and Ar2 and Ar1 are neutral.11. The complex of claim 8 , wherein Ar2 is an anion and Ar1 and Ar3 are neutral.12. The complex of claim 8 , wherein W is a halogen claim 8 , a cyano claim 8 , alkyl claim 8 , alkenyl claim 8 , akynyl claim 8 , alkoxy claim 8 , alkylthio claim 8 , amine claim 8 , phosphine claim 8 , or an optionally substituted aryl or heteroaryl group.14. The complex of claim 8 , wherein each of Ar1 claim 8 , Ar2 claim 8 , and Ar3 is independently unsubstituted or substituted with one more R groups claim 8 , wherein each R group independently represents an alkyl group claim 8 , a haloalkyl group claim 8 , an aralkyl group claim 8 , an alkenyl group claim 8 , alkynyl group claim 8 , an aryl group claim 8 , an amino group claim 8 , a mono- or di-alkylamino group claim 8 , a mono- or diaryl amino group claim 8 , an alkoxy group claim 8 , an aryloxy group claim 8 , a heteroaryloxy group claim 8 , an alkoxycarbonyl group claim 8 , an acyloxy group claim 8 , an acylamino group claim 8 , an alkoxycarbonylamino group claim 8 , an aryloxycarbonylamino group claim 8 , a sulfonylamino group claim 8 , a sulfamoyl group claim 8 , a carbamoyl group claim 8 , an alkylthio group claim 8 , a sulfinyl group claim 8 , an ureido group claim 8 , a phosphoramide group claim 8 , a hydroxyl group claim 8 , a mercapto group claim 8 , a halogen atom claim 8 , a cyano group claim 8 , a sulfo group claim 8 , a carboxyl group claim 8 , a nitro group claim 8 , a hydrazino group claim 8 , a substituted silyl group claim 8 , or a polymerizable group.15. (canceled)1718-. (canceled)19. A phosphorescent emitter comprising the complex of .20. An organic light emitting device comprising the complex of . This application claims priority to U.S. Provisional Patent Application Ser. No. 61/032,818 filed Feb. 29, 2008, which is incorporated by reference herein.This ...

CARBOXYLATE METAL COMPLEX AND CATALYST FOR OLEFIN POLYMERIZATION

The present invention provides a metal complex of group 10 elements of the periodic table having a carboxylate structure represented by formula (C2); a catalyst for polymerization of olefin mainly comprising the metal complex; and a method for producing polymers by homopolymerizing olefin represented by formula (1), polymerizing two or more kinds of the above olefin, or copolymerizing olefin represented by formula (1) with polar group-containing olefin represented by formula (2) (the meaning of the symbols are as set forth in the description) using the catalyst. A metal complex of group 10 elements of the periodic table, in which all of the coordinating atoms to the metal are a hetero atom is stable and useful as a catalyst component for olefin polymerization, and can be used for a long time in homopolymerization of olefin or copolymerization of two or more kinds of olefin. 3. The carboxylate metal complex as claimed in claim 2 , wherein M in formula (C2) is Ni or Pd.4. The carboxylate metal complex as claimed in claim 2 , wherein Rin formula (C2) is hydrocarbon group having 1 to 30 carbon atoms which may be substituted by a halogen atom.5. The carboxylate metal complex as claimed in claim 4 , wherein R1 in formula (C2) is methyl group or trifluoromethyl group.6. The carboxylate metal complex as claimed in claim 5 , wherein Rin formula (C2) is methyl group.7. The carboxylate metal complex as claimed in claim 2 , wherein both of Rand Rin formula (C2) are isopropyl group or cyclohexyl group.8. The carboxylate metal complex as claimed in claim 2 , wherein all of Rs in formula (C2) are a hydrogen atom.9. The carboxylate metal complex as claimed in claim 2 , wherein L in formula (C2) is 2 claim 2 ,6-dimethylpyridine and n is 1.10. A catalyst for olefin polymerization mainly comprising the carboxylate metal complex claimed in .11. A method for producing a polymer characterized in polymerizing olefin represented by formula (1) singly or in combination of two or more kinds ...

Compounds as Ligands for Transition Metal Complexes and Materials Made Thereof, and Use Therefor

The invention relates to novel compounds as ligands for transition metal complexes and materials made thereof that can be used, for example, as emitters in organic light-emitting electrochemical cells (OLEECs). According to the invention, non-fluorinated electron-poor emitter materials are disclosed for the first time that can be used in organic light-emitting electrochemical cells. 15-. (canceled)7. A cationic transition complex comprising a central atom and two structures of a ligand A according to the heterocycle of .9. A material for a light-emitting layer of an organic light-emitting electrochemical cell claim 6 , comprising a transition metal complex with a ligand A according to .10. A material for a light-emitting layer of an organic light-emitting electrochemical cell comprising a transition metal complex comprising a central atom and two structures of a ligand A according to .11. A material for a light-emitting layer of an organic light-emitting electrochemical cell claim 8 , comprising a transition metal complex with a ligand A in combination with a ligand B according to .12. An organic light-emitting electrochemical cell comprising a transition metal complex with a ligand A according to .13. An organic light-emitting electrochemical cell comprising a transition metal complex comprising a central atom and two structures of a ligand A according to .14. An organic light-emitting electrochemical cell comprising a transition metal complex with a ligand A in combination with a ligand B according to . This patent application is a national phase filing under section 371 of PCT/EP2011/058903, filed May 31, 2011, which claims the priority of German patent application 10 2010 023 959.3, filed Jun. 16, 2010, each of which is incorporated herein by reference in its entirety.The invention relates to novel compounds as ligands for transition metal complexes and to materials produced therefrom, which can be used, for example, as emitters in organic light-emitting ...

Novel transition metal complexes and use thereof in organic light-emitting diodes v

Metal complexes comprising at least one polycyclic aromatic ligand and bearing at least one deuterium atom, an organic light-emitting diode comprising at least one inventive metal complex, a light-emitting layer comprising at least one inventive metal complex, an organic light-emitting diode comprising at least one inventive light-emitting layer, the use of the at least one inventive metal complex in organic light-emitting diodes, and a device selected from the group consisting of stationary visual display units such as visual display units of computers, televisions, visual display units in printers, kitchen appliances and advertising panels, illuminations, information panels and mobile visual display units such as visual display units in cellphones, laptops, digital cameras, vehicles, and destination displays on buses and trains, comprising at least one inventive organic light-emitting diode.

RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS

Provided is a catalyst for asymmetric reduction, which can be produced by a convenient and safe production method, has a strong catalytic activity, and has excellent stereoselectivity. The present invention relates to a ruthenium complex represented by the following formula (1): wherein Rrepresents an alkyl group or the like; Y represents a hydrogen atom; X represents a halogen atom or the like; j and k each represent 0 or 1; Rand Reach represent an alkyl group or the like; Rto Reach represent a hydrogen atom, an alkyl group or the like; Z represents oxygen or sulfur; nrepresents 1 or 2; and nrepresents an integer from 1 to 3, a method for producing the ruthenium complex, a catalyst for asymmetric reduction formed from the ruthenium complex, and methods for selectively producing an optically active alcohol and an optically active amine using the catalyst for asymmetric reduction. 4. A method for producing a reduction product by reducing an organic compound in the presence of the ruthenium complex as set forth in and a hydrogen donor.5. A method for producing an optically active alcohol claim 1 , the method comprising reducing a carbonyl group of a carbonyl compound in the presence of the ruthenium complex according to and a hydrogen donor.6. A method for producing an optically active amine claim 1 , the method comprising reducing an imino group of an imine compound in the presence of the ruthenium complex according to and a hydrogen donor.7. The method according to claim 4 , wherein the hydrogen donor is selected from formic acid claim 4 , a formic acid alkali metal salt claim 4 , and an alcohol having a hydrogen atom on the α-position carbon atom substituted with a hydroxyl group.8. The method according to claim 4 , wherein the hydrogen donor is hydrogen.9. A catalyst for reduction claim 4 , comprising the ruthenium complex according to .10. The catalyst according to claim 9 , wherein the catalyst is a catalyst for asymmetric reduction. The present invention ...

Polyhedral oligomeric silsesquioxane (poss) bonded ligands and the use thereof

The present invention relates to POSS-modified ligands and to the use thereof in catalytically effective compositions in hydroformylation.

Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device

As a novel substance having a novel skeleton, an organometallic complex with high emission efficiency which achieves improved color purity by a reduction of half width of an emission spectrum is provided. One embodiment of the present invention is an organometallic complex in which a β-diketone and a six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom are ligands. In General Formula (G1), X represents a substituted or unsubstituted six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom. Further, Rto Reach represent a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms. 10. A light-emitting element comprising the organometallic complex according to .11. A light-emitting device comprising the light-emitting element according to .12. An electronic device comprising the light-emitting device according to .1311. A lighting device comprising the light-emitting device according to claim .16. A light-emitting element comprising the organometallic complex according to .17. A light-emitting device comprising the light-emitting element according to .18. An electronic device comprising the light-emitting device according to .19. A lighting device comprising the light-emitting device according to . One embodiment of the present invention relates to an organometallic complex. In particular, one embodiment of the present invention relates to an organometallic complex that is capable of converting a triplet excited state into luminescence. In addition, one embodiment of the present invention relates to a light-emitting element, a light-emitting device, an electronic device, and a lighting device each using an organometallic complex.Organic compounds are brought into an excited state by the absorption of light. Through this excited state, various reactions (photochemical reactions) are caused in some cases, or luminescence ...

IMIDAZOLIDINE-BASED METAL CARBENE METATHESIS CATALYSTS

The present invention relates to novel metathesis catalysts with an imidazolidine-based ligand and to methods for making and using the same. The inventive catalysts are 5. The metathesis catalyst of claim 3 , wherein at least one of L claim 3 , L claim 3 , R claim 3 , R claim 3 , X claim 3 , and Xmay be linked with at least one of L claim 3 , L claim 3 , R claim 3 , R claim 3 , X claim 3 , and Xto form a bonded ligand array.6. The metathesis catalyst of claim 3 , wherein L may be bonded together with one of X and Xto form a bidentate ligand.7. The metathesis catalyst of claim 3 , wherein L may be bonded together with one of R and Rto form a bidentate ligand.8. The metathesis catalyst of claim 3 , wherein R and Rmay be bonded together.10. The metathesis catalyst of claim 9 , wherein at least one of L claim 9 , L claim 9 , R claim 9 , R claim 9 , R claim 9 , R claim 9 , X claim 9 , and Xmay be linked with at least one of L claim 9 , L claim 9 , R claim 9 , R claim 9 , R claim 9 , R claim 9 , X claim 9 , and Xto form a bonded claim 9 , bidentate claim 9 , or multidentate ligand array.11. The metathesis catalyst of claim 9 , wherein L may be bonded together with one of X and Xto form a bidentate ligand.12. The metathesis catalyst of claim 9 , wherein L may be bonded together with one of R and Rto form a bidentate ligand.13. The metathesis catalyst of claim 9 , wherein R and Rmay be bonded together. The present application claims the benefit of U.S. Provisional Application No. 60/135,493, filed May 24, 1999 by inventors Robert H. Grubbs and Matthias Scholl entitled SYNTHESIS OF RUTHENIUM-BASED OLEFIN METATHESIS CATALYSTS COORDINATED WITH 1,-3-DISUBSTITUTED-4,5-DIHYDRO-(4,5-DI-SUBSTITUTED)-IMEDAZOLE-2-YLIDENE LIGANDS [Attorney Docket No. 20072-0254089 (CIT-2993)] and U.S. Provisional Application No. 60/142,853, filed Jul. 7, 1999 by inventors Robert H. Grubbs and Matthias Scholl entitled IMIDAZOLIDINE- BASED METAL CARBENE METATHESIS CATALYSTS [Attorney Docket No. 20072- ...

Cyclometallated tetradentate platinum complexes

Novel phosphorescent platinum complexes containing tetradentate ligands are provided. The disclosed compounds have three 6-membered metallocycle units in each tertadentate ligand. The disclosed compounds have desirable electronic properties that make them useful when incorporated into a variety of OLED devices.

Novel Imidazolium Salts and Carbene Metal Complexes Based Thereon for Use as Bioanalytical Markers for Biomolecules

The present invention relates to imidazolium salts, particularly imidazolium salts of the general formula I as well as the respective carbene metal complexes and their utilisation as bioanalytical tags for biomolecules. 2. Imidazolium salts according to claim 1 , wherein the groups R claim 1 , R claim 1 , and R claim 1 , where applicable claim 1 , are the same or different and chosen from the group of C-C-n-alkyl groups.3. Imidazolium salts according to claim 1 , wherein n claim 1 , m claim 1 , and q claim 1 , where applicable claim 1 , are zero or 1 and b and l are zero.4. Imidazolium salts according to claim 1 , wherein R″ is a C-C-n-alkyl group.7. Carbene metal complexes according to claim 6 , wherein the metal is chosen from the group consisting of copper claim 6 , iron claim 6 , ruthenium claim 6 , nickel claim 6 , and palladium or from the group consisting of technetium claim 6 , rhenium and cobalt.8. Carbene metal complexes according to claim 6 , wherein the ligand L is chosen from the group consisting ofCO;nitrile;isonitrile;nitrosyl;halogenide ion;hydrogen atom;{'sub': 1', '12', '6', '14', '1', '12', '6', '14', '1', '12', '6', '14', '1', '12', '6', '14', '6', '14', '1', '12', '1', '12, 'C-C-alkyl anion, allyl anion, methylallyl anion, benzyl anion, C-C-aryl anion, C-C-alkoxy anion, C-C-aryloxy anion, C-C-heteroalkyl anion, C-C-heteroaryl anion, C-C-heteroalkoxy anion, C-C-heteroaryloxy anion or C-C-heteroaryloxy anion, which is unsubstituted or the same or differently substituted by one or more C-C-alkyl groups or C-C-heteroalkyl groups, whereby the heteroatoms are chosen from the group B, Al, Ga, In, N, P, As, Sb, Bi, Si, Ge, Sn, Pb, O, S, Se, and Te and wherein the anions are unsubstituted or wholly or partially substituted with one or more than one, same, or different heteroatoms from the same group, in the form of functional groups, wherein the cyclic and aromatic systems are single rings or several annelated or isolated rings;'}primary, secondary, ...

Medicaments Based on Dinuclear Arene Ruthenium Complexes Comprising Bridging Thiolato, Selenolato or Alkoxo Ligands

The present invention provides new complexes and medicaments based on dinuclear ruthenium complexes comprising bridging thiolato or selenolato ligands. The complexes comprise a RuXor a RuXcore, in which each one of said X is independently selected from said bridging ligands, with the proviso that at least one ligand comprises a substituted or unsubstituted phenyl moiety. 123-. (canceled)25. The method of claim 24 ,{'sub': 1', '2', '3, 'wherein X, Xand Xare selected from S and Se;'}{'sub': 7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18, 'claim-text': C4-C20 hydrocarbons optionally comprising 0-15 heteroatoms, with the proviso that said C4-C20 hydrocarbon optionally comprising 0-15 heteroatoms comprises at least one aromatic ring or ring system and/or comprises at least one bioactive moiety, and further from:', 'H, halogens, hydroxyl, carboxylic acid group, nitro and amino, C1-C10 alkyls, C2-C10 alkenyls, C2-C10 alkynyls, C4-C10 aryl, C1-C10 alkoxyl, C2-C10 alkenoxyl, C2-C10 alkynoxyl, C4-C10 aryloxyl, wherein said alkyl, alkoxyl, alkenyl, alkenoxyl, alkynyl, alkynoxyl, may be totally or partially halogenated and may be linear or branched, wherein said aryl and/or an aryl moiety of said aryloxyl, if it is a C4 or a C5 aryl and/or aryloxyl, respectively, it comprises at least on heteroatom, wherein said aryl and aryloxyl may be further substituted, besides with halogen, with C1-C4 alkyl, and wherein substituents on neighbouring carbons of any one or both of the benzene rings in formula (IIa) or (IIb) may be linked so as to form one or more rings fused to said benzene ring., 'wherein substituents R, R, R, R, R, R, R, R, R, R, R, and Rare selected, independently, from26. The method of claim 24 , wherein X claim 24 , Xand Xare S.27. The method of claim 24 , wherein claim 24 , in said R claim 24 , R claim 24 , and R claim 24 , in as far as present claim 24 ,said aryl is a substituted or unsubstituted phenyl; 'wherein substituents of said phenyl, alkyl, ...

SYNTHESIS OF CYCLOMETALLATED PLATINUM(II) COMPLEXES

A single-step method of making tetradentate platinum or palladium complexes is disclosed. The method advantageously allows the formation of a platinum or palladium complex in a single step, even with sterically hindered ligands, without the use of highly reactive intermediates. The compounds made by the disclosed method are useful in OLED applications. 1. A method of preparing a metal complex comprising:(a) combining at least one ligand L with a metal precursor to form a mixture;wherein the ligand L is at least bidentate;wherein the metal precursor is a Pt or Pd compound containing at least one bidentate ligand L′;wherein no halogen is directly connected to the Pt or Pd;(b) reacting the mixture for a sufficient time to form a reaction product;wherein the reaction product has at least two atoms from ligand L bonded to the Pt or Pd, wherein ligand L has at least one anionic carbon donor bonded to Pt or Pd;(c) recovering the reaction product from the mixture.7. The method of claim 2 , wherein rings A claim 2 , B claim 2 , C claim 2 , and D are independently selected from the group consisting of benzene claim 2 , pyridine claim 2 , imidazole claim 2 , and pyrazole.8. The method of claim 2 , wherein at least one of ring A claim 2 , B claim 2 , C claim 2 , and D is benzene.9. The method of claim 2 , wherein two of Z claim 2 , Z claim 2 , Zand Zare CH claim 2 , and two of Z claim 2 , Z claim 2 , Zand Zare N.10. The method of claim 1 , wherein the metal precursor is Pt compound.13. The method of claim 12 , wherein Xand Xare independently selected from the group consisting of O and S.14. The method of claim 12 , wherein Xand Xare O.16. The method of claim 15 , wherein R claim 15 , R claim 15 , and Rare independently selected from the group consisting of alkyl claim 15 , hydrogen claim 15 , deuterium claim 15 , and combinations thereof.17. The method of claim 16 , wherein Ris hydrogen or deuterium claim 16 , and Rand Rare independently selected from the group consisting of ...

Chelating Carbene Ligand Precursors and Their Use in the Synthesis of Metathesis Catalysts

Chelating ligand precursors for the preparation of olefin methathesis catalysts are disclosed. The resulting catalysts are air stable monomeric species capable of promoting various methathesis reactions efficiently, which can be recovered from the reaction mixture and reused. Internal olefin compounds, specifically beta-substituted styrenes, are used as ligand precursors. Compared to terminal olefin compounds such as unsubstituted styrenes, the beta-substituted styrenes are easier and less costly to prepare, and more stable since they are less prone to spontaneous polymerization. Methods of preparing chelating-carbene methathesis catalysts without the use of CuCl are disclosed. This eliminates the need for CuCl by replacing it with organic acids, mineral acids, mild oxidants or even water, resulting in high yields of Hoveyda-type methathesis catalysts. The invention provides an efficient method for preparing chelating-carbene metathesis catalysts by reacting a suitable ruthenium complex in high concentrations of the ligand precursors followed by crystallization from an organic solvent.

Process for preparing transition metal-carbene complexes

Process for preparing cyclometallated transition metal-carbene complexes comprising at least one carbene ligand, which comprises reacting a ligand precursor with a base, an auxiliary reagent and a metal complex comprising at least one metal M 1 (route A) or reacting the ligand precursor with a basic auxiliary reagent and a metal complex comprising at least one metal M 1 (route B). The present invention further relates to the use of an auxiliary reagent selected from among salts comprising at least one metal selected from the group consisting of Ag, Hg, Sb, Mg, B and Al together with a base in a process for preparing cyclometallated metal complexes.

BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS

The present disclosure relates to biaryl diphosphine ligands of the formula (B), processes for the production of the ligands and the use of the ligands in metal catalysts for asymmetric synthesis. The disclosure also relates to intermediates used for the production of the biaryl diphosphine ligand. (Formula (B)) 2. The compound according to claim 1 , wherein Rand Rare independently or simultaneously C-(alkyl) claim 1 , C-(alkenyl) claim 1 , C-(alkynyl) claim 1 , C-(cycloalkyl) or C-(aryl) claim 1 , all of which are optionally substituted.3. The compound according to claim 2 , wherein Rand Rare independently or simultaneously C-(alkyl) claim 2 , C-(alkenyl) claim 2 , C-(alkynyl) claim 2 , C-(cycloalkyl) or phenyl claim 2 , all of which are optionally substituted.4. The compound according to claim 3 , wherein Rand Rare independently or simultaneously methyl claim 3 , ethyl claim 3 , propyl claim 3 , butyl or phenyl claim 3 , all of which are optionally substituted.5. The compound according to claim 4 , wherein Rand Rare independently or simultaneously methyl claim 4 , ethyl or propyl claim 4 , all of which are optionally substituted.6. The compound according to claim 5 , wherein Rand Rare simultaneously methyl.7. The compound according to claim 1 , wherein Rand Rare independently or simultaneously C-(alkyl) claim 1 , C-(alkenyl) claim 1 , C-(alkynyl) claim 1 , C-(cycloalkyl) claim 1 , C-(aryl) claim 1 , C-(heteroaryl)-O—C-(alkyl) claim 1 , —O—C-(aryl) claim 1 , —O—CH—C-(aryl) claim 1 , all of which are optionally substituted.8. The compound according to claim 7 , wherein Rand Rare independently or simultaneously C-(alkyl) claim 7 , C-(alkenyl) claim 7 , C-(alkynyl) claim 7 , C-(cycloalkyl) claim 7 , phenyl claim 7 , C-(heteroaryl)-O—C-(alkyl) claim 7 , —O-phenyl claim 7 , —O—CH-phenyl claim 7 , all of which are optionally substituted.9. The compound according to claim 8 , wherein Rand Rare independently or simultaneously phenyl claim 8 , tolyl (4-methylphenyl) claim 8 ...

Method for producing optically active amine compound

The present invention relates to methods for producing an optically active amine compound via a highly enantioselective hydrogenation reaction of an imine compound, wherein the imine compound is hydrogenated using a ruthenium metal complex having high catalytic activity and represented by Formula (1) RuXYAB  (1) such as RuBr 2 [(S,S)-xylskewphos][(S,S)-dpen].

Formulations for organic electroluminescent devices

The present invention relates to a formulation, in particular for use in organic electroluminescent devices, comprising a carbazole compound, an electron-transport compound, a triplet emitter compound and at least one solvent, where the electron-transport compound encompasses a ketone compound or a triazine compound and where the carbazole compound contains at least two carbazole groups whose N atoms are connected to one another via an aromatic or heteroaromatic ring system. The invention is furthermore directed to organic electro-luminescent devices which comprise the mixtures according to the invention.

TRIPHENYLENE-BASED MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES

The present invention relates to compounds of the formula (1) and (2) which are suitable for use in electronic devices, in particular organic electroluminescent devices. 115-. (canceled)19. The compound according claim 16 , wherein claim 16 , in compounds of the formula (1) where n=0 or in compounds of the formula (4) or formula (4a) claim 16 , X is selected from the group consisting of C(R) claim 16 , Si(R)and N(R) and Rstands claim 16 , identically or differently on each occurrence claim 16 , for an aromatic or heteroaromatic ring system having 5 to 40 aromatic ring atoms claim 16 , which may in each case also be substituted by one or more radicals Rand where two radicals Rmay also form an aromatic ring system with one another;and in that, in compounds of the formula (1) where X=formula (3) or in compounds of the formula (5) or formula (5a), the two triphenylene moieties which are bonded to A are in each case substituted identically and A stands for carbon or silicon;{'sup': 2', '2', '2', '2', '2', '2', '2', '2, 'sub': 2', '2', '2', '2, 'and in that, in compounds of the formula (1) where n=1 or in compounds of the formula (6) or formula (6a), the group X—Y—X is selected from the group consisting of C(R)—O—C(R), Si(R)—O—Si(R), O—BR—O, O—PR—O, O—P(═O)R—O and C(═O)—NR—C(═O);'}and in that, in compounds of the formula (2) or (7) or (7a), the two radicals R are identical.20. A process for the preparation of the compound according to which comprises reacting 1 claim 16 ,12-dilithiotriphenylene derivatives with electrophiles or by reaction of halogen- or amino-substituted triphenylene derivatives in a metal-catalyzed coupling reaction.21. An oligomer claim 16 , polymer or dendrimer containing one or more of the compounds according to claim 16 , where one or more bonds are present from the compound to the polymer claim 16 , oligomer or dendrimer.22. An electronic device which comprises the compound according to .23. An electronic device which comprises the oligomer claim ...

Method for producing complex of trisortho-metalated iridium, light-emitting material using said complex, and light-emitting element

A method for obtaining, with high selectivity as compared to a conventional method of mixing reaction substrates and thereafter reacting the mixture under heating, a facial isomer of tris-orthometallated iridium that is suitably used particularly as an organic electroluminescence device material, among complexes of tris-orthometallated iridium. The method for producing a complex of tris-orthometallated iridium according to the present disclosure includes, in order, a step (1) of preliminarily heating at least one of the complex of orthometallated iridium or the bidentate organic ligand; a step (2) of mixing the complex of orthometallated iridium and the bidentate organic ligand; and a step (3) of reacting the complex of orthometallated iridium and the bidentate organic ligand.

ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS

The present invention provides novel osmium-based electrochemical species for the detection of wide variety of analytes using immunological techniques. The present invention also provides diagnostic kits and test sensors supporting electrode structures that can be used with the osmium-based electrochemical species. The test sensor can be fabricated to support interdigitated arrays of electrodes that have been designed to provide amplification of the electrical signal amplification desired to analyze analytes that may be present at low concentrations. 2. The compound of wherein R and Rare the same and are selected from 2 claim 1 ,2′-bipyridyl claim 1 , 4 claim 1 ,4′-disubstituted-2 claim 1 ,2′-bipyridyl claim 1 , or 5 claim 1 ,5′-disubstituted-2 claim 1 ,2′-bipyridyl substituted with a methyl claim 1 , an ethyl or a phenyl group.3. The compound of wherein L is —(CH)NRand n is an integer between 1 and 10.4. The compound of wherein Q is NR5. The compound of wherein B comprises an epitope recognizable by an antibody capable of specific binding to an analyte.6. The compound of wherein B comprises an epitope capable of binding to an analyte selected from the group consisting of a biowarfare agent claim 1 , an abused substance claim 1 , a therapeutic agent claim 1 , an environmental pollutant claim 1 , a protein or a hormone.7. The compound of wherein X is selected from the group consisting of: chloride claim 1 , bromide claim 1 , iodide claim 1 , and fluoride.8. A method of detecting an analyte in a liquid sample claim 1 , said method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'contacting a portion of said sample with a specific binding partner for said analyte and a redox reversible conjugate, said conjugate comprising the compound of ;'}simultaneously applying a first potential voltage to a first working electrode and a second potential voltage to a second working electrode using a bipotentiostat; andmeasuring a current generated by a portion of the ...

METAL COMPLEX AND USE AS MULTI-ELECTRON CATALYST

The invention is directed to a composition according to the following general formula: [(BL)-(M)-(Ar)-(X)] (A)-5 wherein M is a metal ion, BL is a bidentate ligand having two nitrogen atoms coordinating with a metal ion M, Ar is an, optionally substituted, conjugated cyclic hydrocarbon compound, X is H2O and A is an anion and n in n+ and n− are individually chosen from 1,2,3,4 or 5. The invention is also directed to its precursors and its use as multi-electron catalyst in a water splitting process. 2. The composition according to claim 1 , wherein metal ion M is Ag claim 1 , Au claim 1 , Co claim 1 , Fe claim 1 , Ir claim 1 , Mn claim 1 , Mo claim 1 , Ni claim 1 , Os claim 1 , Pd claim 1 , Pt claim 1 , Re claim 1 , Rh and/or Ru.3. The composition according to claims 2 , wherein M is Ru claims 2 , Ir claims 2 , Mn claims 2 , Co claims 2 , Ni or Os.4. The composition according to claims 2 , wherein M is Ru or Ir.5. The composition according to claim 1 , wherein Ar is an optionally substituted conjugated cyclic hydrocarbon compound having 5 claim 1 , 6 or 8 carbons in the ring.6. The composition according to claim 5 , wherein Ar is cyclopentadiene claim 5 , pentamethylcyclopentadiene claim 5 , benzene claim 5 , mesitylene claim 5 , p-cymene claim 5 , durene claim 5 , hexamethyl benzene claim 5 , cyclooctadiene and/or cyclooctatetradiene.7. The composition according to claim 1 , wherein anion A is Cl claim 1 , Br claim 1 , ClO claim 1 , CHCOO claim 1 , NOPF claim 1 , BF claim 1 , CO and/or SO.8. The composition according to claim 1 , wherein the direct bridge connecting the two nitrogen atoms of the bidentate ligand BL contains two carbon atoms.9. The composition according to claim 8 , wherein BL is an optionally substituted 2 claim 8 ,2′-bipyridine.11. The composition according to claim 10 , wherein [(BL)-(M)-(Ar)—(X)] is [(cy)Ru(Hdcabpy)-OH] claim 10 , wherein cy is p-cymene and Hdcabpy is of 4 claim 10 ,4′-dicarboxylic acid-2 claim 10 ,2′-bipyridine.1222. -. ( ...

Phosphorescent Molecules for Measuring Oxygen and Imaging Methods

Oxygen levels in biological tissue or systems can be measured by the phosphorescence quenching method using phosphorescent porphyrin probes, also referred to as a dendritic oxygen probes, with controllable quenching parameters and defined biodistributions. Provided are a “next generation” of oxygen sensors with substantially improved phosphorescence emission for better imaging capabilities, ease of use, increasing the quantum efficiency (phosphorescence intensity) and extending their range of applicability including constructing a class of oxygen sensors for making measurements in organic media. In addition, provided are methods for synthesizing new porphyrin constructs in which the porphyrin is made less flexible and more planar, changing with decrease internal quenching, and thereby increasing the phosphorescence emission used for oxygen sensing. Additional methods are provided for structurally modifying the dendrimer used to encapsulate the porphyrin phosphor to provide internal quenching of singlet oxygen molecules formed during oxygen measurements. 1. A phosphorescent porphyrin probe , also referred to as a dendritic oxygen probe , effective for oxygen measurement in human or animal tissue , said dendritic oxygen probe comprising a porphyrin having a Pd or Pt core , and a single set of two π-aryl aromatic extensions located opposite to each other on either side of a porphyrin core and radiating therefrom , and to which di-aryl rings dendrons are peripherally attached , forming dendrimers.2. The phosphorescent probe of claim 1 , wherein the di-aryl rings are added to meso unsubstituted or to 5 claim 1 ,15 di-aryl substituted π-extended porphyrins claim 1 , wherein the aryl substitutions are made to meso unsubstituted or 5 claim 1 ,15 di-aryl substituted π-extended porphyrin having aromatic extension arms opposite to each other on either side of the porphyrin core claim 1 , followed by attaching dendrons to unbound termini of the di-aryl rings thereby forming ...

Metathesis Catalysts Containing Onium Groups

Disclosed herein is a general method for the preparation of complexes containing a quaternary onium group in an inert ligand. Some of these complexes may be represented by formula 1: Methods for the preparation of complexes of formula 1, the preparation of intermediates and the use of complexes of formula 1 in metathesis reactions and a method for conducting an olefin metathesis reaction are also described.

QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF

Quinazoline derivatives represented by general formula (1) and quinazoline complexes as protein kinase inhibitors, and their preparation methods are provided. Wherein, in general formula (1), at least one of R and R′ is a group containing an atom capable of coordinating with noble metals, m and n are either the same or different and are integers from 0 to 5. Said quinazoline complex as protein kinase inhibitor is formed by coordination compound containing noble metal and said quinazoline derivative ligand capable of coordinating with noble metal in the coordination compound. Used as tyrosine protein kinase inhibitors, Quinazoline derivatives and quinazoline complexes as protein kinase inhibitors provided by the present invention have exhibited good inhibitory effect on proliferation of various tumor cells including human breast cancer cells line (drug-resistant) MCF-7/A, human breast cancer cell line (sensitive) MCF-7/S, prostate cancer cell PC-3, keratinocytes Colo-16, human non-small cell lung cancer cell line A549, etc. 153-. (canceled)55. The quinazoline complex as protein kinase inhibitor according to claim 54 , wherein said atom capable of coordinating with noble metal in R and/or R′ is one or more selected from the group consisting of oxygen atom claim 54 , nitrogen atom and sulfur atom.56. The quinazoline complex as protein kinase inhibitor according to claim 55 , wherein said atom capable of coordinating with noble metal in R and/or R′ is oxygen atom and/or nitrogen atom; said oxygen atom is oxygen atom in hydroxyl claim 55 , and said nitrogen atom is nitrogen atom in amine group or nitrogen atom in aromatic heterocycle.57. The quinazoline complex as protein kinase inhibitor according to claim 56 , wherein said amine group is an aliphatic amine group claim 56 , said aromatic heterocycle is one selected from the group consisting of imidazole ring claim 56 , pyridine ring claim 56 , 2 claim 56 ,2′-bipyridine ring claim 56 , phenanthroline ring claim 56 , and ...

Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin

The present invention provides pharmaceutical compositions comprising phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV). In some embodiments, such compositions may be useful for treating cancers, including cisplatin- and carboplatin-resistant cancers. The provided phosphaplatin complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum agents that have a different molecular target than those in the art.

Metal Complex Compound, Hydrogen Production Catalyst and Hydrogenation Reaction Catalyst Each Comprising the Metal Complex Compound, and Hydrogen Production Method and Hydrogenation Method Each Using the Catalyst

Provided is a catalyst for producing hydrogen, which catalyst has higher performance than conventional catalysts since, for example, it exhibits a certain high level of activity in an aqueous formic acid solution at high concentration even without addition of a solvent, amine and/or the like. The metal phosphine complex is a metal phosphine complex represented by General Formula (1): MH(CO)L, wherein M represents an iridium, iron, rhodium or ruthenium atom; in cases where M is an iridium or rhodium atom, m=3 and n=2, and in cases where M is an iron or ruthenium atom, m=2 and n=3; and the number n of Ls each independently represent a tri-substituted phosphine represented by General Formula (2): PRRR. The catalyst for producing hydrogen comprises the metal phosphine complex as a constituent component. 2. The metal phosphine complex according to claim 1 , wherein the tri-substituted phosphine represented by the General Formula (2) comprises at least one optionally substituted cyclohexyl group or 4-dialkylaminophenyl group.3. The metal phosphine complex according to claim 1 , wherein the tri-substituted phosphine represented by the General Formula (2) is at least one selected from the group consisting of tri(4-dialkylaminophenyl)phosphine claim 1 , di(4-dialkylaminophenyl)phenylphosphine claim 1 , 4-dialkylaminophenyldiphenylphosphine claim 1 , trimethylcyclohexylphosphine claim 1 , methylcyclohexyldicyclohexylphosphine claim 1 , dicyclohexyl(4-dialkylaminophenyl)phosphine and cyclohexyldi(4-dialkylaminophenyl)phosphine.4. A catalyst for producing hydrogen by the formic acid decomposition reaction (HCOOH→H+CO) claim 1 , the catalyst comprising as a constituent component the metal phosphine complex according to .5. The catalyst for producing hydrogen according to claim 4 , further comprising as a constituent component an amine or a phosphine.6. The catalyst for producing hydrogen according to claim 5 , wherein the amine is at least one amine selected from the group ...

CATALYST COMPLEX WITH CARBENE LIGAND

Catalytic complexes including a metal atom having anionic ligands, at least one nucleophilic carbene ligand, and an alkylidene, vinylidene, or allenylidene ligand. The complexes are highly stable to air, moisture and thermal degradation. The complexes are designed to efficiently carry out a variety of olefin metathesis reactions. 2. A catalytic complex according to wherein Ar is η—CHN or an alkyl substituted derivative thereof claim 1 , p-cymene claim 1 , fluorene claim 1 , or indene.3. A catalytic complex according to wherein the complex is linked to a solid support by means of a link between said anionic ligand and said solid support.4. A catalytic complex according to wherein the complex is linked to a solid support by means of a link between said nucleophilic carbene and said solid support.5. A method of performing ring closing metathesis claim 1 , said method comprising contacting a diene with a catalytic complex of under conditions appropriate claim 1 , and for a time sufficient to produce a cyclic alkene.6. A method according to wherein Ar is η—CHN or an alkyl substituted derivative thereof claim 5 , p-cymene claim 5 , fluorene claim 5 , or indene.8. A method as in wherein the terminal acetylene is substituted at the y-position with hydrogen claim 7 , a vinyl claim 7 , group or a phenyl group claim 7 , wherein the vinyl or phenyl group is optionally substituted with one or more moieties selected from C-Calkyl claim 7 , C-Calkoxy claim 7 , phenyl claim 7 , or a functional group selected from chloride claim 7 , bromide claim 7 , iodide claim 7 , fluoride claim 7 , nitro claim 7 , or dimethylamine.9. A method as in wherein the precursor species is formed from a dimer of the formula [ArMXX]by exposing the dimer to a nucleophilic carbene in a suitable solvent. This application is a continuation of application Ser. No. 13/041,573, filed Mar. 7, 2011, which is continuation of U.S. Pat. No. 7,902,389, issued Mar. 8, 2011, which is a continuation of U.S. Pat. No. 7, ...

Bisamineazaallylic Ligands And Their Use In Atomic Layer Deposition Methods

Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising bisamineazaallylic ligands are provided. Also provided are bisamineazaallylic ligands useful in the methods of the invention and metal coordination complexes comprising these ligands. 2. The metal complex of claim 1 , wherein L is a bisamineazaallylic ligand.4. The metal complex of wherein L is halogen or methyl.5. The metal complex of prepared by a method comprising:{'sub': 1', '2', '2', '3', '4', '2', '2', '2', '1', '2', '2', '2', '2', '3', '4, 'a) reacting an aldehyde compound having a formula RRN—CH—COH with a compound having a formula RRN—CHCHNHto form a reaction product represented by formula RRN—CH—CH═N—CH—CH—NRR;'}b) treating the reaction product with lithium hexamethyldisilazide (LHMDS) to produce a ligand coordinated with a lithium ion, and;c) forming the transition metal complex by reacting the ligand coordinated with the lithium ion and a transition metal halide. This application is a divisional under 35 U.S.C. §121 of U.S. application Ser. No. 13/189,644, filed Jul. 25, 2011, which claims priority to U.S. Provisional Application Ser. No. 61/407,970, filed Oct. 29, 2010 the disclosures of which are hereby incorporated by reference in their entirety.The present invention relates generally to methods of depositing thin films of elemental metal and to metal coordination complexes useful in such methods. In particular, the invention relates to coordination complexes of metal cations with multidentate azaallylic ligands and their use in atomic layer deposition processes.Deposition of thin films on a substrate surface is an important process in a variety of industries including semiconductor processing, diffusion barrier coatings and dielectrics for magnetic read/write heads. In the semiconductor industry, in particular, miniaturization requires atomic level control of thin film deposition to produce conformal coatings on high aspect structures. One method ...

Platinum(ii) complexes for oled applications

The current invention relates to novel platinum(II) based organometallic materials. These materials show high emission quantum efficiencies and low self-quenching constant. Also provided are high efficiency, green to orange emitting organic light-emitting diode (OLED) that are fabricated using platinum(II) based organometallic materials as the light-emitting material. The organometallic materials of the invention are soluble in common solvents; therefore, solution process methods such as spin coating and printing can be used for device fabrication. The devices fabricated from these materials show low efficiency roll-off.

Novel ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof

The present invention relates to novel Ruthenium catalysts and related borohydride complexes, and the use of such catalysts, inter alia, for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e., synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to the novel uses of certain pyridine Ruthenium catalysts.

Fluorinated 2-Amino-4-(Benzylamino)Phenylcarbamate Derivatives

The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.

LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND

The invention provides novel organometallic complexes useful as olefin metathesis catalysts. The complexes have an N-heterocyclic carbene ligand and a chelating carbene ligand associated with a Group 8 transition metal center. The molecular structure of the complexes can be altered so as to provide a substantial latency period. The complexes are particularly useful in catalyzing ring closing metathesis of acyclic olefins and ring opening metathesis polymerization of cyclic olefins. 3. The complex of claim 2 , wherein Rand Rare C-Calkyl or C-Caryl claim 2 , and Y is a substituted or unsubstituted methylene or ethylene linkage.5. The complex of claim 4 , wherein Rand Rare C-Calkyl or C-Caryl claim 4 , and Y is a substituted or unsubstituted methylene or ethylene linkage.6. The complex of claim 5 , wherein Rand Rare phenyl acid Y is ethylene.9. A method for catalyzing an olefin metathesis reaction claim 1 , comprising contacting an olefinic reactant with the complex of under reaction conditions selected to enable olefin metathesis.14. The complex of claim 1 , wherein the complex is a positional isomer Land the ligand containing Q bonded to M is a cis orientation.15. The complex of claim 1 , wherein the complex is a positional isomer having Land the ligand containing Q bonded to M in a trans orientation.16. The complex of claim 2 , wherein the complex is a positional isomer having Land the ligand containing Q bonded to M in a cis orientation.17. The complex of claim 2 , wherein the complex is a positional isomer having Land the ligand containing Q bonded to M in a trans orientation.18. The complex of claim 4 , wherein the complex is a positional isomer laving Land the ligand containing Q bonded to M in a cis orientation.19. The complex of claim 4 , wherein the complex is a positional isomer having Land the ligand containing Q bonded to M in a trans orientation.20. The complex of claim 7 , wherein the complex is a positional isomer having Land the ligand containing Q ...

Iridium complex with methyl-d3 substitution

Novel organic compounds comprising ligands with deuterium substitution are provided. In particular, the compound is an iridium complex comprising methyl-d 3 substituted ligands. The compounds may be used in organic light emitting devices to provide devices having improved color, efficiency and lifetime.

NEW IRIDIUM-BASED COMPLEXES FOR ECL

Novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in the electrochemiluminescence based detection of an analyte. 2. The compound according to claim 1 , wherein the linker Q is a straight or branched saturated claim 1 , unsaturated claim 1 , unsubstituted or substituted C1-C20 alkyl chain claim 1 , or a 1 to 20 atom chain with a backbone consisting of carbon atoms and one or more heteroatoms selected from O claim 1 , N and S.3. The compound according to claim 1 , wherein the linker Q is a saturated C1-C12 alkyl chain or a 1 to 12 atom chain with a backbone consisting of carbon atoms and one or more heteroatoms selected from O claim 1 , N and S.4. The compound according to claim 1 , wherein the functional group Y is selected from the group consisting of carboxylic acid claim 1 , N-hydroxysuccinimide ester claim 1 , amino group claim 1 , halogen claim 1 , sulfhydryl claim 1 , maleimido claim 1 , alkynyl claim 1 , azide and phosphoramidite.5. A conjugate comprising a compound according to and covalently bound thereto an affinity binding agent.6. The conjugate of claim 5 , wherein the affinity binding agent is selected from the group consisting of antigen and antibody claim 5 , biotin or biotin analogue and avidin or streptavidin claim 5 , sugar and lectin claim 5 , nucleic acid or nucleic acid analogue and complementary nucleic acid and receptor and ligand.7. The conjugate according to claim 5 , wherein said affinity binding agent is a nucleic acid or an antibody.8. A method for measuring an analyte by an in vitro method claim 5 , the method comprising the steps of:a) providing a sample suspected or known to comprise the analyte;{'claim-ref': {'@idref': 'CLM-00005', 'claim 5'}, 'b) contacting said sample with a conjugate according to under conditions appropriate for formation of an analyte conjugate complex; and'}c) measuring the complex formed in step (b) and thereby obtaining a ...

PHARMACEUTICAL COMPOSITION CONTAINING CYCLOMETALATED N-HETEROCYCLIC CARBENE COMPLEXES FOR CANCER TREATMENT

The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase. 2. The method of claim 1 , comprising administering an effective amount of a pharmaceutical composition having the formula (I) claim 1 , wherein claim 1 ,{'sup': '3+', 'M is Au;'}X is a carbon atom;{'sup': 1', '2', '3', '4', '5, 'R, R, R, R, and Rare each —H;'}{'sup': 6', '7, 'sub': '3', 'Rand Rare each —CH;'}{'sub': 2', '3, 'A is a OSOCFanion;'}n is +1;b is −1; andy is 1 (complex 1).10. The method of claim 1 , comprising administering an effective amount of a pharmaceutical composition having the formula (I) claim 1 , wherein claim 1 ,{'sup': '2+', 'M is Pt;'}X is a nitrogen atom;{'sup': 1', '2', '3', '4', '5, 'R, R, R, R, and Rare each —H;'}{'sup': 6', '7, 'sub': '3', 'Rand Rare each —CH;'}{'sub': '6', 'A is a PFanion;'}n is +1;b is −1; andy is 1 (complex 11).11. The method of claim 1 , comprising administering an effective amount of a pharmaceutical composition having the formula (I) claim 1 , wherein claim 1 ,{'sup': '2+', 'M is Pt;'}X is a nitrogen atom;{'sup': 1', '2', '3', '4', '5, 'R, R, R, R, and Rare each —H;'}{'sup': 6', '7, 'sub': 2', '5, 'Rand Rare each —CH;'}{'sub': '6', 'A is a PFanion;'}n is +1;b is −1; andy is 1 (complex 12).12. The method of claim 1 , comprising administering an effective amount of a pharmaceutical composition having the formula (I) claim 1 , wherein claim 1 ,{'sup': '2+', 'M is Pt;'}X is a nitrogen atom;{'sup': 1', '2', '3', '4', '5, 'R, R, R, R, and Rare each —H;'}{'sup': 6', '7, 'sub': 3', '7, 'Rand Rare each —CH;'}{'sub': '6', 'A is a PFanion;'}n is +1;b is −1; andy is 1 (complex 13).13. The ...

Binuclear metal complex, and organic electroluminescence element comprising same

A novel binuclear metal complex containing a biimidazole as a bridging ligand. The binuclear metal complex can be used as a material for an organic electroluminescence element.

Metal-based thiophene photodynamic compounds and their use

Compositions of the invention include tunable metal-based thiophene photodynamic compounds useful as therapeutic agents and as in vivo diagnostic agents for treating or preventing diseases that involve hyperproliferating cell etiology including cancer and diseases associated with hyperproliferating cells. The compositions are also useful for treating infectious diseases and for pathogen disinfection.

Novel Compound, Novel Ligand, Novel Transition Metal Complex, and Catalyst Including Novel Transition Metal Complex

The invention provides novel ligands for transition metal complexes which exhibit high coordination power with respect to metals by being free of substituents at the positions ortho to phosphorus or arsenic and which have electron-withdrawing power comparable to the highest level known in conventional ligands. A ligand of the invention includes a compound represented by General Formula (1): RRRA or General Formula (2): RRA-Y-ARRand having a total of 15 to 110 carbon atoms. In the formulae, A is phosphorus or arsenic; R, R, Rand Rare each independently a substituted pyridyl group having optionally different electron-withdrawing groups bonded to the positions meta to the atom A as well as hydrogen atoms bonded to the positions ortho to the atom A; and Y is a divalent group derived from a C, optionally substituted and optionally heteroatom-containing, aliphatic, alicyclic or aromatic compound or from ferrocene. 1. A compound represented by General Formula (1) or (2) and having a total of 15 to 110 carbon atoms:{'br': None, 'sup': 1', '2', '3, 'RRRA\u2003\u2003(1)'}{'br': None, 'sup': 1', '2', '3', '4, 'RRA-Y-ARR\u2003\u2003(2)'}{'sup': 1', '2', '3', '4, 'sub': '2-20', '(wherein A is phosphorus or arsenic; R, R, Rand Rare each independently a substituted pyridyl group having optionally different electron-withdrawing groups bonded to the positions meta to the atom A as well as hydrogen atoms bonded to the positions ortho to the atom A; and Y is a divalent group derived from a C, optionally substituted and optionally heteroatom-containing, aliphatic, alicyclic or aromatic compound or from ferrocene).'}2. The compound according to claim 1 , wherein the electron-withdrawing group is at least one selected from the group consisting of a perhaloalkyl group having 1 to 4 carbon atoms claim 1 , a halogen claim 1 , nitro group claim 1 , cyano group claim 1 , pentafluorophenyl group claim 1 , tetrafluoropyridyl group claim 1 , heptafluorotolyl group claim 1 , 2 claim 1 ,6- ...

PREPARATION OF A FAC-ISOMER FOR A TRIS HOMOLEPTIC METAL COMPLEX

The present application provides a use of a mixture comprising less than 75 vol. % of an organic solvent and more than 25 vol. % of water in a preparation of a fac-isomei of a tris homoleptic metal complex, in the presence or the absence of an added salt, and with the proviso that when an added salt contains at least two oxygen atoms, it is used in an amount such that the molar ratio of the salt to the metal in a metal compound used as starting material is less than 1. The present application also provides a method of preparing a fac-isomer for a tris homoleptic metal complex using the mixture. 1. A use of a mixture comprising less than 75 vol. % of an organic solvent and more than 25 vol. % of water in a preparation of afac-isomer of a tris homoleptic metal complex , in the presence or the absence of an added salt , with the proviso that when an added salt contains at least two oxygen atoms , it is used in an amount such that the molar ratio of the salt to the metal in a metal compound used as starting material is less than 1.2. The use of in accordance with claim 1 , wherein the preparation of the fac-isomer of a tris homoleptic metal complex is conducted in the absence of any added salt.3. The use in accordance with claim 1 , wherein the mixture comprises not more than 70 vol. % of an organic solvent and at least 30 vol. % of water claim 1 , preferably not more than 66 vol. % of an organic solvent and at least 34 vol. % of water claim 1 , more preferably not more than 60 vol % of an organic solvent and at least 40 vol % of water.4. The use in accordance with claim 1 , wherein the fac-isomer of a tris-homoleptic metal complex is prepared from a dihalo-bridged dimer claim 1 , preferably a dichloro- or dibromo-bridged dimer.5. The use in accordance with claim 1 , wherein the fac-isomer of a tris homoleptic metal complex is prepared from a metal halide complex claim 1 , preferably a metal chloride complex or a metal bromide complex.6. The use in accordance with claim ...

PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The invention relates to the platinum N-heterocycle derivatives of general formula (I) 18.-. (canceled)10. The method according to claim 9 , wherein said cancer is a solid cancer.11. The method according to claim 10 , wherein said cancer is a gastric cancer claim 10 , colorectal cancer claim 10 , lung cancer claim 10 , breast cancer claim 10 , or prostate cancer.12. The method according to claim 9 , where said cancer is a liquid tumour.13. The method according to claim 12 , wherein said cancer is a leukemia.14. The method according to claim 9 , wherein said N-Heterocyclic carbene-platinum complex is:trans-diiodo(N-cyclohexylamine)(1,3-dimethylimidazol-2-ylidene)platinum(II);trans-dibromo(N-cyclohexylamine)(1,3-dimethylimidazol-2-ylidene)platinum(II);trans-dichloro(N-cyclohexylamine)(1,3-dimethylimidazol-2-ylidene)platinum(II);trans-dinitrato(N-cyclohexylamine)(1,3-dimethylimidazol-2-ylidene)platinum(II);trans-diiodo(N-cyclohexylamine)(1,4-dimethyl-1,2,4-triazol-3-ylidene)platinum(II);trans-dibromo(N-cyclohexylamine)(1,4-dimethyl-1,2,4-triazol-3-ylidene)platinum(II);trans-dichloro(N-cyclohexylamine)(1,4-dimethyl-1,2,4-triazol-3-ylidene)platinum(II);trans-dinitrato(N-cyclohexylamine)(1,4-dimethyl-1,2,4-triazol-3-ylidene)platinum(II);trans-diiodo(N-cyclohexylamine)(1-methyl-3-(cyclohexylmethyl)imidazol-2-ylidene)platinum(II);trans-dibromo(N-cyclohexylamine)(1-methyl-3-(cyclohexylmethyl)imidazol-2-ylidene)platinum(II);trans-dichloro(N-cyclohexylamine)(1-methyl-3-(cyclohexylmethyl)imidazol-2-ylidene)platinum(II);trans-dinitrato (N-cyclohexylamine)(1-methyl-3-(cyclohexylmethyl)imidazol-2-ylidene)platinum(II);trans-diiodo (N-cyclohexylamine)(1-methyl-3-phenylimidazol-2-ylidene)platinum(II);trans-dibromo (N-cyclohexylamine)(1-methyl-3-phenylimidazol-2-ylidene)platinum(II);trans-dichloro(N-cyclohexylamine)(1-methyl-3-phenylimidazol-2-ylidene)platinum(II);trans-dinitrato (N-cyclohexylamine)(1-methyl-3-phenylimidazol-2-ylidene)platinum(II);trans-diiodo(N-tetrahydropyranyl-4- ...

METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES

A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes. 4. The composition of claim 1 , wherein at least two of Lthrough Lcombine to form the single ligand having two coordination sites to M claim 1 , and the single ligand having two coordination sites to M comprises a ligand selected from the group consisting of DPE claim 1 , HDPA claim 1 , MeDPA claim 1 , MDPA claim 1 , phen claim 1 , PrDPA claim 1 , HexDPA claim 1 , DPAE claim 1 , PPE claim 1 , and PyPrOH.5. The composition of claim 1 , wherein Land Lcombine to form a first single ligand having two coordination sites to M claim 1 , Land Lcombine to form a second single ligand having two coordination sites to M claim 1 , and each of the first and second single ligands having two coordination sites to M independently comprises a ligand selected from the group consisting of DPE claim 1 , HDPA claim 1 , MeDPA claim 1 , MDPA claim 1 , phen claim 1 , PrDPA claim 1 , HexDPA claim 1 , DPAE claim 1 , PPE claim 1 , and PyPrOH.6. The composition of claim 1 , wherein M is rhodium.7. The composition of claim 1 , wherein at least two of Lthrough Lcombine to form the single ligand having two coordination sites to M claim 1 , and the single ligand having two coordination sites to M is represented by Formula II in which Ris selected from the group consisting of:alkyl groups terminating in an alkynyl-linked peptide moiety comprising an antibody or a carbohydrate, andPEGylated groups terminating in an alkynyl-linked peptide moiety comprising an antibody or a carbohydrate.8. The composition of claim 1 , wherein at least two of Lthrough Lcomprise NH.9. The composition of claim 8 , wherein at least two of Lthrough Lcombine to form the single ligand having two coordination sites to M claim 8 , and the single ligand having two coordination sites to M is selected ...

N-HETEROCYCLIC CARBENE METALLACYCLE CATALYSTS AND METHODS

The present invention generally relates to materials and methods for catalytic reactions, including transition metal-catalyzed cross-coupling reactions. The materials may be stable metal complexes that do not require special handling or processing conditions. In some cases, materials of the invention advantageously may be synthesized in one synthetic step without the need for isolation of intermediate compounds. Also, materials of the invention may be synthesized from inexpensive and readily available starting materials, under relatively mild reaction conditions that do not require the exclusion of air, water, and the like. In some embodiments, the material is a N-heterocyclic carbene metallacycle complex. Such materials and methods may be useful in the production of fine chemicals, advanced materials and specialty polymers. 2. A method as in claim 1 , wherein each Ris independently hydrogen claim 1 , alkyl claim 1 , cycloalkyl claim 1 , alkoxy claim 1 , amino claim 1 , aryl claim 1 , heteroaryl claim 1 , or substituted derivatives thereof; A is carbon claim 1 , nitrogen claim 1 , phosphorus claim 1 , oxygen claim 1 , or sulfur; C is nitrogen claim 1 , phosphorus claim 1 , oxygen claim 1 , or sulfur; D is nitrogen claim 1 , phosphorus claim 1 , arsenic claim 1 , antimony claim 1 , oxygen claim 1 , sulfur claim 1 , selenium claim 1 , or tellurium; and n is an integer between 1 and 3.311-. (canceled)12. A method as in claim 1 , wherein one of the three components is a palladium-containing compound.1314.-. (canceled)15. A method as in claim 1 , wherein one of the three components is an N-heterocyclic carbene ligand precursor.2029-. (canceled)31. A method as in claim 1 , wherein the at least three components are not joined by a bond prior to the reacting.34. A composition as in claim 33 , wherein each Ris independently hydrogen claim 33 , alkyl claim 33 , cycloalkyl claim 33 , alkoxy claim 33 , amino claim 33 , aryl claim 33 , heteroaryl claim 33 , or substituted ...

New palladium catalyst, method for its preparation and its use

The invention relates to palladium(0) tris{tri-[3,5-bis(trifluoromethyl)-phenyl]-phosphine} complex of formula (I), as well as to its preparation and use. This compound is outstandingly stable, and can be used as catalyst with excellent results.

HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF

The present invention provides novel high-valent palladium complexes. The complexes typically include multi-dentate ligands that stabilize the octahedral coordination sphere of the palladium(IV) atom. These complexes are useful in fluorinating organic compounds and preparing high-valent palladium fluoride complexes. The invention is particularly useful for fluorinating compounds with F for PET imaging. 211.-. (canceled)12. The palladium complex of claim 1 , wherein Rand Rtaken together with the atoms to which they are attached form an aryl ring and Rand Rtaken together with the atoms to which they are attached form an aryl ring.1317.-. (canceled)18. The palladium complex of claim 1 , wherein R claim 1 , R claim 1 , Rand Rare each a 5-membered heteroaryl ring.1953.-. (canceled)56. (canceled)57. The palladium complex of claim 55 , wherein Cy taken together with the nitrogen atom to which it is attached forms a heteroaryl ring.5876.-. (canceled)79. (canceled)81. (canceled)82. The palladium complex of claim 80 , wherein each Ris hydrogen.83. (canceled)84. The palladium complex of claim 80 , wherein Z is a halide claim 80 , acetate claim 80 , tosylate claim 80 , azide claim 80 , tetrafluoroborate claim 80 , tetraphenylborate claim 80 , tetrakis(pentafluorophenyl)borate claim 80 , [B[3 claim 80 ,5-(CF)CH]] claim 80 , hexafluorophosphate claim 80 , phosphate claim 80 , sulfate claim 80 , perchlorate claim 80 , trifluoromethanesulfonate or hexafluoroantimonate.85. (canceled)86. The palladium complex of claim 80 , wherein F comprises F.87. The palladium complex of claim 80 , wherein F comprises F.90115.-. (canceled)117152.-. (canceled)154. (canceled)155. A method of fluorination claim 55 , wherein the palladium complex of is mixed with F— to produce a palladium (IV) complex and subsequently said palladium (IV) complex is reacted with an organic compound under conditions sufficient to fluorinate the compound claim 55 , thereby providing a fluorinated organic compound.156157 ...

Phosphorescent materials

Novel organic compounds containing a twisted aryl group are provided. In particular, the compounds provided contain a 2-phenylpyridine ligand having a twisted aryl group on the pyridine portion of the ligand. The compounds may be used in organic light emitting devices, particularly as emitting dopants. Devices comprising the compounds containing twisted aryl may demonstrate improved color, efficiency, stability and manufacturing. Additionally, methods are provided for making homoleptic Ir (III) compounds which may contain a twisted aryl.

PHOTOSENSITIZERS AND USE THEREOF FOR GENERATING HYDROGEN FROM WATER

The invention relates to novel complexes and to the use thereof as photosensitizers for generating hydrogen from water. 2. The compound of in claim 1 , wherein X is oxygen or sulfur.4. The compound of claim 1 , wherein:{'sup': 1', '30, 'Rto Reach, independently, represent hydrogen, halogen, straight-chain or branched alkyl having 1-20 carbon atoms or phenyl; or'}{'sup': 1', '30, 'Rto Rare joined to one another in pairs by a single or double bond to form aromatic or aliphatic rings.'}5. (canceled)6. A catalyst system claim 1 , comprising at least one compound of .7. The catalyst system as claimed in claim 6 , further comprising at least one water reduction catalyst and at least one electron donor.8. A process for preparing hydrogen by reduction of water claim 6 , the process comprising reducing water in the presence of the catalyst system of to form hydrogen.9. Hydrogen obtained by the process of .11. The compound of claim 2 , wherein:{'sup': 1', '30, 'Rto Reach, independently, represent hydrogen, halogen, straight-chain or branched alkyl having 1-20 carbon atoms or phenyl; or'}{'sup': 1', '30, 'Rto Rare joined to one another in pairs by a single or double bond to form aromatic or aliphatic rings.'} The present invention relates to novel complexes and their use as photosensitizers for producing hydrogen from water.Alternative energy generation, for example wind power or solar energy, are playing an increasingly important role in the worldwide supply of energy. The associated fluctuation in the quantity of energy provided requires the use of energy stores for bridging energy minimum phases (night, lack of wind, etc.). Hydrogen is in this context considered to be a promising energy store.In addition, hydrogen is a valuable starting material for the preparation of a wide variety of important basic chemicals, e.g. ammonia and methanol, and specialty chemicals which can be prepared by hydrogenation. A future hurdle for the chemical utilization of hydrogen is that the ...

PROCESS FOR THE HOMOGENEOUSLY CATALYZED AMINATION OF ALCOHOLS WITH AMMONIA IN THE PRESENCE OF A COMPLEX CATALYST WHICH COMPRISES NO ANIONIC LIGANDS

The invention relates to a process for preparing primary amines by alcohol amination of alcohols with ammonia with the elimination of water, where the alcohol amination is carried out under homogeneous catalysis in the presence of at least one complex catalyst which comprises ruthenium and at least one at least bidental donor ligand, but no anionic ligands. 1. A process for preparing a primary amine , the process comprising performing alcohol amination of an alcohol with ammonia and elimination of water under homogeneous catalysis in the presence of a complex catalyst comprising ruthenium and an at least bidental donor ligand , but no anionic ligands.6. The process according to claim 2 , wherein Rand Rare unsubstituted cyclohexyl.8. The process according to claim 2 , wherein n=0 in the complex catalyst.9. The process according to claim 1 , where the alcohol has a primary or secondary alkyl group.10. The process according to claim 1 , where the primary amine is a monoamine claim 1 , an alkanolamine claim 1 , a diamine claim 1 , a triamine claim 1 , or a polyamine.11. The process according to claim 1 , where the alcohol has at least two secondary alcohol groups.12. The process according to claim 1 , where the alcohol is selected from the group consisting of isosorbide claim 1 , isomannide claim 1 , isoidide and a mixture thereof.14. The process according to claim 13 , where the ruthenium-comprising catalyst precursor is selected from the group consisting of [Ru(CO)] claim 13 , [Ru(CO)(ethylene)] claim 13 , [Ru(COD)(OAc)] claim 13 , [Ru(COD)(2-methylallyl)] claim 13 , [Ru(CO)Cl] claim 13 , [Ru(CO)Cl] claim 13 , [RuCl*HO] claim 13 , [Ru(acetylacetonate)] claim 13 , [Ru(PPh)(CO)(H)Cl] claim 13 , [Ru(PPh)(CO)Cl] claim 13 , [Ru(PPh)(CO)(H)] claim 13 , [Ru(PPh)Cl] and [Ru(COD)Cl]. This patent application claims the benefit of pending U.S. provisional patent application Ser. No. 61/674,423 filed on Jul. 23, 2012, incorporated in its entirety herein by reference.The present ...

Synthetic Method for Phosphaplatin Compounds

This application discloses novel methods and processes for preparation and purification of phosphaplatin compounds. The improvements of the synthetic methods and purification processes include, but are not limited to, efficient and reproducible large-scale preparation of these useful pharmaceutical agents in high quality and good yield. 1. A method of preparing a monomeric platinum pyrophosphate complex , or a salt thereof , comprising: mixing a platinum dihalide compound with a pyrophosphate salt in a solvent system comprising water and at least one wetting agent , maintaining a reaction mixture wherein the platinum dihalide compound reacts with the pyrophosphate salt to form the monomeric platinum pyrophosphate complex; precipitating out the monomeric platinum pyrophosphate complex; and isolating the monomeric platinum complex from the reaction mixture.2. The method of claim 1 , wherein said precipitating comprises adjusting pH of the reaction mixture to about or below 2 and cooling the reaction mixture to about or below 20° C.3. The method of claim 1 , further comprising concentrating the reaction mixture by distilling out a portion of solvent(s) prior to said precipitating.4. The method of claim 2 , wherein said adjusting pH comprises adding to the reaction mixture a solution of an organic or inorganic acid.5. The method of wherein said adjusting pH comprises adding the reaction mixture to a solution of an organic or inorganic acid.6. The method of claim 1 , wherein said wetting agent is a water-miscible organic solvent.7. The method of claim 6 , wherein the water-miscible organic solvent is a lower alkyl alcohol.8. (canceled)9. The method of claim 1 , wherein the platinum dihalide compound is at a concentration so that at least about 65% of platinum precipitates out as the monomeric platinum pyrophosphate complex directly from the reaction mixture upon adjusting pH of the reaction mixture to about or below 2 at a temperature of about or below 20° C.10. ( ...

Organometallic Anti-Cancer Complexes

An anti-cancer ruthenium complex containing organometallic triruthenium with two maltol ligands is claimed. 2. An anti-cancer ruthenium complex of claim 1 , wherein L represents a carbonyl.3. An anti-cancer ruthenium complex of claim 1 , wherein Y is O.4. An anti-cancer ruthenium complex of claim 1 , wherein n is 1 and X is O.5. An anti-cancer ruthenium complex of claim 1 , wherein Ris —H or —CH.6. An anti-cancer ruthenium complex of claim 1 , wherein Ris —CH.7. An anti-cancer ruthenium complex of claim 1 , wherein Ris —H or —CH.8. An anti-cancer ruthenium complex of claim 1 , wherein Ris —H.9. An anti-cancer ruthenium complex of claim 1 , wherein Z is O.10. An anti-cancer ruthenium complex of claim 1 , wherein n is 1 and X is S.11. An anti-cancer ruthenium complex of claim 1 , wherein n is 1 claim 1 , X is O claim 1 , Y is O claim 1 , Z is O claim 1 , Ris —CH claim 1 , Ris —H claim 1 , and L is carbonyl. This application claims the benefit of U.S. Provisional Application No. 61/472,977, filed Apr. 7, 2011, which is incorporated by reference.This invention relates to an anti-cancer ruthenium complex.Currently, there is great interest in the synthesis of organometallic compounds as anticancer agents.In recent years, several ruthenium-based compounds have attracted attention due to their promising anticancer activity.Cisplatin and its derivatives are already widely used in the clinic as anticancer agents. Nonetheless, these drugs have severe toxic side effects, are inactive against certain cancers, and can often develop resistance to tumors.Therefore the quest for innovative organometallic drugs are in increasing demand.Maltol, a 4-pyrone (2-methyl-3-hydroxy-4-pyrone) (L) has antioxidativeand iron chelating properties.Pyrones are bioactive compounds present in many natural products such as steroids, kojic acid, and anticoagulant warfarin and a class of important metal chelators with versatile medicinal applications. Hartinger and his coworkers have reported maltol- ...

METAL COMPLEXES

The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes. 115-. (canceled)17. The compound according to claim 16 , wherein M is selected from the group consisting of chromium claim 16 , molybdenum claim 16 , tungsten claim 16 , rhenium claim 16 , ruthenium claim 16 , osmium claim 16 , rhodium claim 16 , iridium claim 16 , nickel claim 16 , palladium claim 16 , platinum claim 16 , copper claim 16 , silver and gold claim 16 , in particular iridium and platinum.18. The compound according to claim 16 , wherein one of the two bridge atoms in the group Y represents a carbon atom and in that the other bridge atom is selected from C claim 16 , N or O claim 16 , where the atoms may in each case be substituted by radicals R.21. The compound according to claim 16 , wherein X stands for CR and preferably for CH.22. The compound according to claim 16 , wherein the substituent R in the ortho-position to the metal coordination represents a group which is likewise coordinated to the metal M.24. The compound according to claim 16 , wherein L′ is selected claim 16 , identically or differently on each occurrence claim 16 , from the group consisting of carbon monoxide claim 16 , nitrogen monoxide claim 16 , alkylcyanides claim 16 , arylcyanides claim 16 , alkylisocyanides claim 16 , arylisocyanides claim 16 , amines claim 16 , phosphines claim 16 , phosphites claim 16 , arsines claim 16 , stibines claim 16 , nitrogen-containing heterocycles claim 16 , carbenes claim 16 , hydride claim 16 , deuteride claim 16 , the halides F claim 16 , Cl claim 16 , Br and I claim 16 , alkylacetylides claim 16 , arylacetylides claim 16 , cyanide claim 16 , cyanate claim 16 , isocyanate claim 16 , thiocyanate claim 16 , isothiocyanate claim 16 , aliphatic or aromatic alcoholates claim 16 , aliphatic or aromatic thioalcoholates claim 16 , amides claim 16 , carboxylates claim 16 , aryl groups claim 16 , O ...

RUTHENIUM-DIAMINE COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND

Provided is a ruthenium complex that is represented by general formula (1*) and is useful as an asymmetric reduction catalyst. 4. (canceled)6. A catalyst for asymmetric reduction claim 2 , consisting of the ruthenium complex according to .7. A method for producing an optically active alcohol claim 2 , comprising reducing a carbonyl group of a carbonyl compound in the presence of the ruthenium complex according to and a hydrogen donor.8. A method for producing an optically active amine claim 2 , comprising reducing an imino group of an imine compound in the presence of the ruthenium complex according to and a hydrogen donor.9. The production method according to claim 7 , wherein the hydrogen donor is selected from formic acid claim 7 , alkali metal formates claim 7 , and alcohols having a hydrogen atom on a carbon atom at an α-position of a carbon atom substituted with a hydroxyl group.10. The production method according to claim 7 , wherein the hydrogen donor is hydrogen gas.11. A catalyst for asymmetric reduction claim 3 , consisting of the ruthenium complex according to .12. A catalyst for asymmetric reduction claim 5 , consisting of the ruthenium complex according to .13. A method for producing an optically active alcohol claim 3 , comprising reducing a carbonyl group of a carbonyl compound in the presence of the ruthenium complex according to and a hydrogen donor.14. A method for producing an optically active alcohol claim 5 , comprising reducing a carbonyl group of a carbonyl compound in the presence of the ruthenium complex according to and a hydrogen donor.15. A method for producing an optically active amine claim 3 , comprising reducing an imino group of an imine compound in the presence of the ruthenium complex according to and a hydrogen donor.16. A method for producing an optically active amine claim 5 , comprising reducing an imino group of an imine compound in the presence of the ruthenium complex according to and a hydrogen donor.17. The production ...

Metal Complexes with N-Aminoamidinate Ligands

The invention relates to new metal complexes having N-aminoamidinate ligands, more particularly metal complexes having N,N′-bis(dimethylamino)acetamidinate, N,N′-bis(dimethylamino)formamidinate, N-dimethylaminoacetamidinate or N-dimethylamino-N′-isopropyl-acetamidinate ligands as well as to their preparation and use. The metal complexes are characterized by a five-membered chelate ring. The metal complexes are formed with the metals from the main groups of the PTE, but also with transition-group elements such as tantalum (Ta), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu) or zinc (Zn), and also with precious metals such as palladium (Pd). 123-. (canceled)25. The metal complex according to claim 24 , wherein{'sup': '1', 'sub': 3', '2', '5', '6', '5, 'Ris CH, CH, CH, tolyl, 2,6-diisopropylphenyl or 2,4,6-trimethylphenyl (mesityl),'}{'sup': 2', '3, 'sub': 3', '2', '5, 'Rand Rindependently of one another are hydrogen, CHor CH,'}{'sup': '4', 'sub': 3', '2', '3', '2', '2', '5', '2, 'Ris hydrogen, CH, NH, N(CH)or N(CH),'}{'sub': 3', '2', '5', '3', '7', '4', '9', '6', '5', '6', '4', '3', '4', '3', '2', '2', '4', '8, 'sup': −', '−', '−', '−', '−', '−', '−', '−', '−', '−', '−', '−', '−', '−', '−', '−', '−', '−, 'X is methylide (CH), ethylide (CH), isopropylide (iso-CH), tert-butylide (tert-CH), the phenylide anion (CH), the ortho-, meta-, or para-tolylide anion [CH(CH)], the thiophen-2-ylide anion (CHS), methylato (MeO), ethylato (EtO), tert-butylato (tert-BuO), MeS, MeSe, (tert-Bu)S, (tert-Bu)Se, dimethylamido (NMe), diethylamido (NEt), methylethylamido (NMeEt) or N-pyrrolidido [NCH], and'}{'sup': t', '2−, 'Y is the imido group [NBu].'}26. The metal complex according to claim 24 , wherein the radical X is a hydride anion (H) claim 24 , chloride (Cl) claim 24 , bromide (Br) claim 24 , methylide (CH) claim 24 , ethylide (CH) claim 24 , dimethylamide (NMe) or diethylamide (NEt).27. The metal complex according to claim 24 , wherein L is pyridine claim 24 , dioxane claim 24 , ...

Phosphorescent emitters with phenylimidazole ligands

Phosphorescent materials are provided, where the materials comprise a coordination compound having at least one ligand L 3 having Formula (I): wherein A and B are each independently a 5-membered or 6-membered carbocyclic or heterocyclic ring; wherein R A , R B , R C , and R D each represent mono, di, tri, tetra substitutions, or no substitution; wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , and Z 8 are each selected from N or C; wherein at least one of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , and Z 8 is N; wherein one of Z 1 , Z 2 , Z 3 , and Z 4 is C that is bonded to N of A; wherein Z is selected from the group consisting of BR, NR, PR, O, S, Se, C═O, S═O, SO 2 , CRR′, SiRR′, and GeRR′; wherein R, R′, R A , R B , R C , and R D are described herein; wherein L 3 is coordinated to a metal M 1 ; and wherein L 3 may be linked with other ligands to comprise a tridentate, tetradentate, pentadentate, or hexadentate ligand. Devices, such as organic light emitting devices, comprising such compounds are also provided.

NOVEL PLATINUM-CARBENE COMPLEXES AND USE THEREOF AS MEDICAMENTS

Disclosed are novel platinum-carbene complexes and use thereof as medicinal products. 13. Compound of formula I according to claim 1 , for use as a medicinal product.14. Pharmaceutical composition comprising a compound of formula I according to as active ingredient claim 1 , and a pharmaceutically acceptable vehicle.15. Pharmaceutical composition claim 1 , comprising a compound of formula I according to as active ingredient claim 1 , and a pharmaceutically acceptable vehicle claim 1 , used in the treatment of cancers claim 1 , in particular in the treatment of a cancer selected from cervical cancer claim 1 , glioma claim 1 , colon cancer claim 1 , breast cancer claim 1 , pancreatic cancer claim 1 , prostate cancer claim 1 , liver cancer claim 1 , lung cancer claim 1 , stomach cancer claim 1 , intestinal cancer claim 1 , cancer claim 1 , melanoma claim 1 , multiple myeloma. The present invention relates to novel platinum-carbene complexes and use thereof as medicinal products.Certain derivatives of platinum are known anticancer agents. The best known among them, cisplatin, is one of the anticancer agents most frequently used throughout the world. However, the application of cisplatin in chemotherapy remains very restricted owing to limitations on its activity with respect to cancer cells. In fact, cisplatin is only active against a limited spectrum of cancer cells. Certain cancer cell lines display a natural resistance to cisplatin, while certain other cancer cells can develop an acquired resistance.Moreover, as a medicinal product cisplatin has several drawbacks, for example significant side-effects such as nephrotoxicity, neurotoxicity, or emetogenesis.Moreover, the main method of administration of cisplatin is still intravenous administration, as cisplatin has low solubility in water (1 mg/ml).Recently, a new family of metal complexes, the N-heterocyclic carbene complexes, has attracted the attention of scientists for their anticancer activity.The carbene ...

PROCESS FOR PREPARING PLATINUM-CARBENE COMPLEXES

Described is a process for preparing platinum-carbene complexes. 2. Process according to claim 1 , in which solvent is selected from ethanol claim 1 , methanol claim 1 , dichloromethane claim 1 , tetrahydrofuran claim 1 , toluene claim 1 , ethyl acetate.3. Process according to claim 1 , carried out in the absence of solvent claim 1 , Lbeing liquid at the reaction temperature and performing the role of solvent.4. Process according to claim 1 , comprising the addition of a base selected from a tertiary amine claim 1 , in particular selected from triethylamine claim 1 , or diisopropylethylamine claim 1 , when the ligand Lis in the form of salt.5. Process according to claim 1 , in which the salt of the ligand Lis in the form of ammonium salt claim 1 , in particular ammonium hydrochloride or ammonium trifluoroacetate.6. Process according to claim 1 , in which the temperature of the reaction is 10° C. to 65° C.7. Process according to claim 1 , in which the reaction between the compound of formula I and the ligand Lis carried out in the presence of ethanol as solvent claim 1 , at a temperature from 45° C. to 65° C. claim 1 , in particular at 55° C.8. Process according to claim 1 , in which the reaction between the compound of formula I and the ligand Lis carried out in the presence of dichloromethane as solvent claim 1 , at a temperature from 10° C. to 35° C. claim 1 , in particular at 20° C.10. Process according to claim 9 , carried out without solvent claim 9 , the ligand Lbeing liquid at the reaction temperature.11. Process according to claim 9 , in which NaXc is in excess with respect to Xa and Xb claim 9 , when Xa is different from Xb.12. Process according to claim 9 , optionally without the addition of NaXc claim 9 , when Xa and Xb are identical.13. Process according to claim 9 , in which the reaction between the compound of formula III and the ligand Lis carried out in the presence of a base claim 9 , in particular a base selected from sodium carbonate claim 9 , ...

Light-emitting element, light-emitting device, electronic device, and lighting device

A light-emitting element having high external quantum efficiency is provided. A light-emitting element having a long lifetime is provided. A light-emitting layer is provided between a pair of electrodes. The light-emitting layer is a stack of a first light-emitting layer, which contains a first phosphorescent compound, a first organic compound having an electron-transport property, and a second organic compound having a hole-transport property and is provided on the anode side, and a second light-emitting layer, which contains at least a second phosphorescent compound and the first organic compound having an electron-transport property. A combination of the first organic compound and the second organic compound forms an exciplex.

HYDROXAMIC ACID DERIVATIVES

The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: 2. A method of alleviating , relieving , altering , remedying , ameliorating , improving or affecting a neoplastic disease or an immune disease according to , the method comprising administering to a subject in need thereof an effective amount of a compound or salt of , wherein Z is deleted , CH , O , CO , NH , SO , OC(O) , C(O)O , C(O)S , NHC(O) , C(O)NH , OC(O)NH , NHC(O)O , or NHC(O)S; m is 5 , 6 , 7 , or 8.3. A method of alleviating , relieving , altering , remedying , ameliorating , improving or affecting a neoplastic disease or an immune disease according to , the method comprising administering to a subject in need thereof an effective amount of a compound or salt of , wherein Q is an aryl or heteroaryl.4. A method of alleviating , relieving , altering , remedying , ameliorating , improving or affecting a neoplastic disease or an immune disease according to , the method comprising administering to a subject in need thereof an effective amount of a compound or salt of , wherein Q is a 9-10 membered aryl or heteroaryl.8. A method of alleviating claim 1 , relieving claim 1 , altering claim 1 , remedying claim 1 , ameliorating claim 1 , improving or affecting a neoplastic disease according to claim 1 , wherein said neoplastic disease is selected from the group consisting of lung cancer claim 1 , head and neck cancer claim 1 , central nervous system cancer claim 1 , prostate cancer claim 1 , testicular cancer claim 1 , colorectal cancer claim 1 , pancreatic cancer claim 1 , liver cancer claim 1 , stomach cancer claim 1 , biliary tract cancer claim 1 , esophageal cancer claim 1 , gastrointestinal stromal tumor claim 1 , breast cancer ...

PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

The present disclosure relates to novel pharmaceutical compositions comprising a nanoparticle associated with, tether to, or encapsulating a platinum-based active pharmaceutical agent. The platinum-based drug is released from the nanoparticles in a controlled fashion. Also contemplated are methods of making the nanoparticles, as well as methods for using them in the treatment or prevention of diseases or conditions. One embodiment relates to phenanthriplatin nanoparticles and methods of using and making the same. 2. The compound of claim 1 , wherein X is a halogen.3. The compound of or claim 1 , wherein X is Cl.4. The compound of claim 1 , wherein X is —O(C═O)Rand Ris hydrogen claim 1 , alkyl claim 1 , aryl claim 1 , arylalkyl claim 1 , or cycloalkyl claim 1 , wherein each of the alkyl claim 1 , aryl claim 1 , arylalkyl claim 1 , and cycloalkyl is optionally substituted with one or more suitable substituents.5. The compound of claim 1 , wherein X is formyl claim 1 , acetate claim 1 , propionate claim 1 , butyrate claim 1 , benzoate claim 1 , or tosylate.6. The compound of any one of to claim 1 , wherein L each is ammonia.7. The compound of any one of to claim 1 , wherein at least one L is an amine.8. The compound of any one of to claim 1 , wherein Y is N.9. The compound of any one of to claim 1 , wherein the heteroaromatic is a monocyclic heteroaromatic claim 1 , a bicyclic heteroaromatic claim 1 , or a tricyclic heteroaromatic.11. The compound of claim 10 , wherein R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , and Reach is independently selected from a group consisting of hydrogen claim 10 , halogen claim 10 , and aryl.13. The compound of claim 12 , wherein Ris halogen or aryl.15. The compound of claim 14 , wherein Ris halogen or aryl.17. The compound of claim 16 , wherein Ris halogen or aryl.19. The compound of claim 18 , wherein Rand Rare connected to form an optionally substituted cycloalkyl.21. The compound of claim 20 , wherein ...

Platinum Complexes and Their Use

The invention relates to platinum complexes and their use in biomedical applications, like in vitro and in vivo imaging and cell staining. The present invention provides new materials and their use as imaging agent. The formation of luminescent aggregates can allow a switch of the emission leading to a dynamic label and on the formation of soft assemblies, which, in some cases, are even more emissive than the isolated corresponding species 2. The platinum(II) complex according to claim 1 , wherein L and/or L′ comprise on remote sites —SO claim 1 , —OSO claim 1 , -phosphonium claim 1 , —COO claim 1 , alkylammonium claim 1 , aminoacid claim 1 , phosphate.4. The platinum(II) complex according to formula (I) of claim 1 , wherein the tridentate ligand is dianionic and L is a neutral monodentate ligand coordinating through nitrogen claim 1 , phosphorus claim 1 , arsenic claim 1 , carbon.6. The platinum(II) complex according to formula (I) of claim 1 , wherein L coordinates through phosphorus and L is PAr claim 1 , PR claim 1 , P(OR).7. The platinum(II) complex according to formula (I) of claim 1 , wherein L coordinates through arsenic and L is AsAr claim 1 , AsR.8. The platinum(II) complex according to formula (I) of claim 1 , wherein L coordinates through carbon and L is a N-heterocyclic carbene claim 1 , carbonyl.9. The platinum(II) complex according to formula (I) of claim 1 , wherein the tridentate ligand is mono-anionic and L is a mono-anionic ligand selected from the group comprising —Cl claim 1 , —Br claim 1 , —I claim 1 , —CN claim 1 , —NCS claim 1 , —NSC claim 1 , —NCO claim 1 , —SR claim 1 , —SAr claim 1 , —OR claim 1 , NaHPO claim 1 , HCO claim 1 , carboxylate claim 1 , —OAr claim 1 , azolates claim 1 , pyrrolates claim 1 , ArO.11. The platinum(II) complex according to claim 1 , wherein the ligand is covalently bound to biomolecules selected from the group comprising a polypeptide or protein claim 1 , a nucleoside or a nucleotide chain and a sugar or sugar ...